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I INTRODUCTION 
1 NATURAL PRODUCTS AS ANTICANCER AGENTS 
 
Since ancient times natural products have played a major role in the treatment of 
diseases. The American Indians used plant extracts from Podophyllum peltatum to 
effectively treat skin cancers. Podophyllotoxin is the main constituent of this plant’s 
root and belongs to the group of anticancer agents known as podophyllins. Among 
this group etoposide is found, which is in regular use for the treatment of testicular 
teratoma and small-cell lung cancer (1).  
Further discoveries based upon folk medicine were the substances vinblastine and 
vincristine, constituents of the plant Vinca rosea, which have significantly contributed 
to the successful treatment of cancer. These discoveries led to the beginning of a 
screening program for antitumor agents (see Table I.1) by the US National Cancer 
Institute (NCI) in 1960. Between 1960 and 1982 about 35,000 plant samples were 
tested, primarily against mouse leukemia cell lines. The most effective drug obtained 
from the screening was paclitaxel (Taxol), originally isolated from the bark of Taxus 
brevifolia (1,2). 
In 1985, the NCI started a new program in which extracts from plants, animals and 
microorganisms (increasingly those of marine origin) were tested against a panel of 
60 human cancer cell lines (1). The intention was to detect compounds that are 
active against solid tumors, which would have been missed in the original screen. 
And, in fact, almost 60% of drugs approved for cancer treatment today are of natural 
origin (3, 4).  
The majority of chemotherapeutic drugs used in cancer therapy induce death in 
malignant cells through apoptosis or other kinds of programmed cell death. The 
inactivation of this cell death mechanism is a fundamental hallmark of cancer and 
leads to drug resistance. Therefore, compounds with unusual mechanisms of action 
are needed to circumvent chemoresistance. Natural compounds have the advantage 
of greater diversity than synthetic chemical libraries (5). Especially the chemical and 
biological diversity of the marine environment has not been acquired for a long time 
yet and provides great potential for the discovery of antitumor agents with novel 
molecular modes of action. 
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Table I.1 Anticancer agents derived from natural origin in development or clinical use (adapted 
from 2, 4, 5) 
 
Plant-derived anticancer agents  
Compound  Source Status 
Etoposide Podophyllum peltatum  Phase III/IV 
Vinblastine, vinchristine Vinca rosea Phase III/IV 
Paclitaxel Taxus brevifola, Taxus baccata Phase III/IV 
  
Microbe-derived anticancer agents  
Compound  Source Status 
Bleomycin Streptomyces verticillus Phase III/IV 
Daunomycin, doxorubicin Streptomyces sp Phase III/IV 
Epothilone  Sorangium cellulosum Phase III/IV 
   
Marine-organism-derived anticancer agents  
Compound  Source Status 
Bryostatin 1 Bugula neritina Phase I/II 
Ecteinascidin-743 Ecteinascidia turbinate Phase I/II 
Spongistatin 1 Hyrtios altum Preclinical 
 
 
2 THE CEPHALOSTATINS 
 
Until the mid 1960s, investigation of natural products with marine origin was 
essentially non-existent. Since then, about 10,000 new structures have been isolated 
from marine microorganisms, sponges and e.g. marine invertebrates (1).  
A promising group of compounds with marine origin comprises the family of 
cephalostatins (6, 7, 8, 9, 10, 11, 12, 13, 14). The cephalostatins were isolated by 
Prof. G. R. Pettit from the South African marine tube worm Cephalodiscus gilchristi 
Ridewood (family Cephalodiscidae). Until today, 19 members of this family have 
been characterized, all of which show the same unique growth inhibitory profile 
(Figure I.1) in the NCI-60 cell line screen.  
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Cephalostatin 1 Cephalostatin 2
 
Figure I.1 Fingerprint of cytotoxic profile of cephalostatin 1 and 2 evaluated by the NCI-60 
screen (September 2005).  
The zero value represents the mean of all cell lines tested. The bars indicate the deviation of the mean 
data obtained from the individual cell line from the overall mean and marks the sensitivity of the cell 
lines for cephalostatin 1 or 2 (negative bars, less sensitive; positive bars, more sensitive) GI50: 50% 
growth inhibition in the 2 days cytotoxicity assay. 
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Surprisingly, the NCI compare analysis between cephalostatin and any other 
compound of the NCI standard agent database shows no apparent correlation (best 
correlation 0.5 with teniposide), suggesting that the cephalostatins might employ 
unique signaling pathways, differing from any other anticancer drug. First studies 
carried out by our group support this notion (15, 16, 17).  
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Figure I.2 Chemical structure of cephalostatin 1, 2, 10 and 12 
 
Cephalostatin 1 and 2 are proven to be the most potent cephalostatins in the NCI-60 
panel, with a GI50 value of 1 nM (see Figure I.1). In addition to the in vitro screen, 
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cephalostatin 1 and 2 were successfully tested in vivo on several xenografts like 
leukemia and melanoma.  
Although the cytotoxicity profile of the cephalostatins does not differ (see Figure I.1), 
their potency varies depending on the chemical composition (Figure I.2). Structure-
activity studies on different cephalostatins revealed that the Northern part is the most 
shared unit among the cephalostatins and is also strongly associated with antitumor 
activity (18). Cephalostatin 10 shows dose dependencies comparable to cephalo-
statin 1 and 2 (6, 7, 10), whereas an increased level of hydroxylation in the Southern 
part results in decreased antitumor activity, as in the case of cephalostatin 12 (18).  
 
 
3 AIM OF THE STUDY 
 
Cephalostatin has been intensively studied by our research group in the last years. 
The suggestion based on the NCI compare analysis that cephalostatin differs from 
other chemotherapeutic drugs known so far was confirmed by investigating the 
substance in Jurkat leukemia T cells. Cephalostatin-induced cell death is not 
dependent on the CD95/caspase-8 pathway and does not induce the formation of the 
apoptosome (15), although caspase-9 is an important initiator caspase for 
cephalostatin in Jurkat T cells (17). Further, the induction of endoplasmic reticulum 
stress could be shown for cephalostatin and that caspase-4 is an initiator caspase 
that partially contributes to caspase-9 activation (17). 
The release of different mitochondrial proteins into cytosol is a hallmark of apoptosis. 
Cephalostatin was found to induce an early and predominant Smac release, whereas 
cytochrome c could not be detected in the cytosol (15). This fact deserves attention 
and asks for the release mechanism and the impact of Smac on cephalostatin-
mediated apoptosis. 
The aim of the present work was to further investigate the underlying mechanism and 
characteristics of cephalostatin induced cell death based on previous work of our 
group (15, 16, 17), with the following main topics: 
1.  Is cephalostatin-induced apoptosis restricted to Jurkat T cells? 
2.  How is the selective Smac release mediated by cephalostatin? 
3.  Does Smac release influence apoptosis induction by cephalostatin? 
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4 PROGRAMMED CELL DEATH 
 
The balance between cell division and cell death is of utmost importance for the 
development and homeostasis of a multicellular organism. Deregulation of either 
process has pathologic consequences and can lead to disturbed embryogenesis, 
neurodegenerative diseases, autoimmunity and the development of cancer. 
Therefore, the balance between life and death is strictly controlled and damaged or 
unnecessary cells are eliminated by a process called programmed cell death (PCD) 
(19, 20).  
NECROSIS APOPTOSIS
Secondary necrosis
Phagocytosis  
 
Figure I.3 Overview of apoptotic and necrotic cell death 
Apoptosis is characterized by cell shrinkage, chromatin condensation and fragmentation of the cell in 
membrane enclosed apoptotic bodies. These are engulfed by macrophages (phagocytosis), thus 
preventing inflammation. In contrast, in necrosis the cell swells and the membrane ruptures. As a 
consequence cellular content is released into the surrounding tissue and inflammation is induced. 
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The classical ultrastructural studies of Kerr et al. (21) shed light on at least two 
distinct types of cell death, namely apoptosis and necrosis (Figure I.3). Apoptosis is 
the most common and best characterized form of PCD and was held synonymously 
for PCD over a long time. It is characterized by typical morphological changes such 
as cell shrinkage, chromatin condensation and cleavage by endonucleases and 
plasma membrane blebbing. Finally, the cell is fragmented into apoptotic bodies. 
These compact membrane-enclosed structures contain the cytosol and cell 
organelles. The “packaging” of the intracellular content prevents an inflammatory 
response, since the apoptotic bodies are engulfed by macrophages and thus 
removed from the tissue. An important step in this is the exposure of 
phosphatidylserine on the cell surface, which mediates the recognition of the 
apoptotic bodies by the macrophages. The morphological changes are a 
consequence of highly conserved, genetically controlled molecular and biochemical 
events, most notably mediated by caspases, a family of cysteine proteases activated 
in apoptosis (20). 
Necrosis is – in contrast to apoptosis – an uncontrolled, passive form of death. It is 
usually the consequence of exposure e. g. to high concentrations of cytotoxic agents 
or of pathophysiological conditions, such as infection and ischemia. The swelling of 
the cell and rupture of the plasma membrane is a characteristic event in necrosis, 
resulting in the release of cellular content into the surrounding tissue and extensive 
inflammation. Typical attributes of apoptotic cell death like DNA fragmentation and 
formation of apoptotic bodies are absent in necrosis (20).  
In recent years, it has become evident that the classic distinction of apoptosis and 
necrosis is a simplification of a highly complex system. Although caspase-mediated 
apoptosis is the underlying cell death program in many settings, it is unlikely that this 
mechanism is the only protection of an organism against unwanted and potentially 
harmful cells. Indeed, multiple alternative cell death pathways – even completely 
caspase independent ones – as well as crosstalk of PCD mechanisms are described. 
The various types of PCD share a common feature, namely that they are executed 
by active cellular processes (22, 23, 24). Since the characterization of signal 
transduction in alternative death styles is still in progress, one approach to 
classification is the nuclear morphology of the dying cell. Table I.2 gives an overview 
of characteristics related to different types of cell death, including morphological and 
biochemical features known so far. 
Another approach is to classify caspase-independent cell death according to the 
cellular organelles involved. Thus, several models have been proposed to categorize 
PCD, but well defined terms are difficult to create and are probably artificial due to 
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the overlapping and commonly used signal transductions pathways between the 
different cell death mechanisms. 
 
Table I.2 Characteristics of different types of cell death adapted from (23, 25, 26) 
 
Type of cell 
death 
Morphological changes Biochemical 
features 
 Nucleus Cell 
membrane 
Cytoplasm  
Apoptosis chromatin condensation, 
nuclear fragmentation, 
DNA laddering 
 
blebbing packaging into 
apoptotic bodies 
caspase-dependent 
Autophagy partial chromatin 
condensation, DNA-
fragmentation very late, 
if at all 
 
blebbing increased number of 
autophagic vesicles 
caspase-independ., 
increased 
lysosomal activity 
Mitotic 
catastrophe 
multiple micronuclei, 
nuclear fragmentation 
 
no consensus on the distinctive 
morphological appearance by now 
caspase-independ. 
(at early stage) 
Necrosis clumping and random 
degradation of nuclear 
DNA 
swelling, 
rupture 
increased vacuolation, 
organelle degradation, 
mitochondrial swelling 
no energy 
requirement  
 
 
5 APOPTOSIS SIGNAL TRANSDUCTION 
 
Apoptosis is a tightly regulated and highly conserved cell death program which 
requires the interaction of multiple factors. It can be triggered by various stimuli from 
outside (receptor mediated) or inside (intracellular stress) the cell. Upon such a signal 
caspases (cysteine-dependent aspartate-specific proteases) are activated in 
classical apoptosis, leading to cell death. 
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5.1 CASPASES 
 
Although the first caspase, interleukin-1β-converting enzyme (ICE or caspase-1), 
was identified in humans, the critical involvement of caspases in apoptosis was 
discovered in the model organism Caenorhabditis elegans. There, the gene ced-3 
(cell death abnormality-3) was found to encode a cysteine protease, an essential 
component in developmental cell death that is closely related to the mammalian ICE. 
Since then, at least 14 distinct mammalian caspases have been identified, 12 of 
which are human. (27, 28) 
 
5.1.1 CLASSIFICATION, STRUCTURE AND ACTIVATION 
 
Caspases can be classified according to their structure, function and preferred 
substrates.  
 
Short Prodomain CARD
INFLAMMATION
DED
8,10 2,9,123,6,7,14 1,4,5,11
APOPTOSIS
CASPASES
 
 
Figure I.4 Classification of caspases based on their prodomain structure or function 
Caspases containing a long prodomain with a CARD (caspases 1, 2, 4, 5, 9, 11, 12) can be divided 
upon their function in inflammatory (caspases 1, 4, 5, 11) and apoptotic (caspases 2, 9, 12) caspases. 
Caspases-8 and 10 possess two DEDs in their long prodomain and belong to the apoptotic family 
members. Caspases 3, 6, 7 and 14 are apoptotic effector caspases with short prodomain. 
 
If caspases are divided into groups by their structural characteristics, two main 
categories – caspases with long or short prodomain – are formed (Figure I.4).  
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Long prodomains comprise structural motifs in the death domain superfamily, 
including the caspase activation and recruitment domain (CARD) and the death 
effector domain (DED). Caspases with long prodomain (caspases 1, 2, 4, 5, 8, 9, 10, 
11, 12) are enabled to interact with other proteins by these structures. This plays an 
important role in apoptotic signaling, since CARD and DED are the responsive 
elements for the recruitment of initiator caspases into death- or inflammation-inducing 
signaling complexes, where caspases are activated. Caspases 3, 6, 7 and 14 have 
short prodomains and are activated by other caspases upon proteolytic cleavage (27, 
28,29). 
Classification of caspases by their primary function leads to two groups comprised of 
inflammatory and apoptotic caspases, whereas the latter can be divided in initiator 
(caspases 2, 8, 9, 10, 12) and effector (caspases 3, 6, 7, 14) caspases (27).  
 
Active site
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Figure I.5 Schematic representation of proteolytic caspase activation (modified from 31) 
Activation proceeds by cleavage of the N-terminal domain at Asp119, Asp296 and Asp316 (all 
caspase-1 numbering convention) leading to a large (p20) and a small (p10) subunit. The activity and 
specificity determining residues (R179, H237, C285 and R341) are brought into the necessary 
structural arrangement for catalysis. Cys285 is the catalytic nucleophile. The active caspase is a 
tetramer of two heterodimers, each comprising a large and a small subunit and an active site. 
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All caspases are synthesized as catalytically inactive zymogens. The zymogens 
consist of the different N-terminal prodomains described above followed by a large 
subunit of approximately 20 kDa (p20) and a small subunit of 10 kDa (p10). The 
subunits are separated by a small linker sequence (30) (see Figure I.5).  
To become catalytically active a procaspase must undergo conformational changes 
and usually has to be cleaved to produce its mature form. Mature caspases are 
formed by association of two monomers, with each monomer comprising the large 
(p20) and the small (p10) subunits. Each tetramer contains two active sites formed by 
residues of the large and small subunit (31, 32).  
Effector caspases are activated by initiator caspases through removal of the 
N-terminal prodomain and the linker peptide within the protease domain by cleavage 
at specific internal Asp residues that separate the large and small subunits. As a 
consequence, a conformational change occurs and the catalytic activity of the 
effector caspase is enhanced (31). How initiator caspases are activated is not fully 
understood. Two models have been proposed, namely the induced proximity and the 
proximity-induced dimerization model, the latter stating that the initiator caspases are 
recruited to large protein complexes, brought into close proximity and get activated 
upon dimerization (32). At present, there are different complexes described like the 
death inducing signaling complex (DISC), the apoptosome and the PIDDosome. 
 
5.1.2 SUBSTRATES 
 
Caspases recognize at least four (caspase-2 five) contiguous amino acids in their 
substrates P4-P3-P2-P1 and cleave after the C-terminal P1, which is usually an 
aspartate. The P3 position is a glutamine residue for all examined caspases, 
whereas the P4 position varies among different groups of caspases. Effector 
caspases cleave numerous proteins, including some that are responsible for 
structural integrity of the cell, as the DNA repair enzyme PARP (poly ADP-ribose 
polymerase), which is cleaved by caspase-3. Initiator caspases can activate effector 
caspases by proteolytic cleavage but have many other targets in the cell. For 
example, caspase-2 can cleave the protein golgin-160, which controls the integrity of 
the Golgi complex. A prominent caspase-8 substrate is the Bcl-2 family member Bid. 
After cleavage, Bid translocates to the mitochondria, thus promoting cytochrome c 
release (27). Overall, more than 280 caspase substrates are identified to date (33). 
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5.1.3 REGULATION 
 
Because caspases play an important role in apoptosis initiation, their expression and 
activation state must be tightly regulated. Caspase regulation is achieved by 
transcriptional and posttranscriptional mechanisms. The conserved IAP (inhibitor of 
apoptosis) protein family can inhibit the enzymatic activity of caspases. Furthermore, 
caspase can be removed through proteasomal degradation promoted by IAPs. The 
IAP proteins were originally identified in the genome of baculovirus on the basis of 
their ability to suppress apoptosis in infected host cells. At least eight IAPs have been 
found in mammals (34, 35, 36) (see Figure I.6). 
 
Bruce/Apollon
ILP2
ML-IAP/Livin
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NAIP
c-IAP1
c-IAP2
 
 
Figure I.6 Schematic representation of the inhibitor of apoptosis protein family (36) 
IAPs have at least one baculoviral IAP repeat (BIR) domain. Additionally, most IAPs have other 
distinct functional domains such as the NACHT domain, the leucine-rich repeats (LRRs) and the RING 
(really interesting new gene) domain. The latter is an E3 ligase that presumably directs targets to the 
ubiquitin-proteasome degradation system. Bruce has an ubiquitin-conjugation (UBC) domain that is 
found in many ubiquitin-conjugating enzymes. (BIR, baculoviral IAP-repeat; cIAP, cellular IAP; IAP, 
inhibitor of apoptosis protein; ILP, IAP-like protein; ML-IAP, melanoma IAP; NAIP, neuronal apoptosis-
inhibitory protein; NACHT, domain found in NAIP; XIAP, X-chromosome-linked IAP.) 
 
The hallmark of IAPs is the baculoviral IAP repeat (BIR) domain, a ~80 amino acid 
zinc binding domain. XIAP, the most extensively studied IAP member contains three 
BIR domains with different functions: BIR3 potently inhibits the activity of processed 
caspase-9, whereas the linker region between BIR1 and BIR2 targets caspase-3 and 
-7. The IAP mediated inhibition of caspases is antagonized by a family of proteins 
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that contain an IAP-binding motif like the mitochondrial protein Smac/DIABLO (see 
chapter I5.3.1) and Omi/HtrA2. Except for survivin, all other IAPs contain other 
functional domains such as a RING domain, an E3 ligase that presumably directs 
targets to the ubiquitin proteasome degradation system (34, 35).  
Survivin, the smallest member of the IAP family with a single BIR domain, is 
transcriptionally regulated by the oncogenic transcription factor STAT3 (37). The BIR 
domain of survivin is closely related to the BIR3 of XIAP and several studies showed 
that survivin is capable of binding caspases -3, -7 and -9 but this is still 
controversially discussed (38, 39). Besides its function in controlling apoptosis, the 
IAP member survivin seems to regulate the mitotic progression and the production of 
the survivin protein is upregulated in G2/M phase. 
 
5.2 EXTRINSIC PATHWAY 
 
There are two alternative pathways – the extrinsic and the intrinsic pathway - that 
initiate apoptosis depending on the origin of the death stimuli. The extrinsic pathway 
is mediated by death receptors on the cell surface and has a crucial role during 
development and for the immune system. The death receptors (DR) belong to the 
tumor necrosis factor (TNF) receptor superfamily, characterized by an extracellular 
ligand binding domain and an intracellular death domain. In mammals several death 
receptors are known as TNF-R1, TRAIL or CD95 (= Fas, APO-1), the latter being the 
most extensively studied. The TNF receptor superfamily includes the decoy 
receptors, which lack a functional death domain, thus building a negative regulation 
mechanism. (19, 40) 
The extrinsic pathway (Figure I.7) is initiated upon binding of an extracellular ligand 
such as CD95L to its receptor (in this case CD95). After ligation, micro-aggregates 
are formed on the cell surface leading to the attraction of the intracellular adaptor 
protein FADD (Fas-associated death domain protein) via the death domains. FADD, 
in turn recruits the inactive caspase-8 or -10 zymogens through interaction with their 
death effector domain (DED) to the so called DISC (death inducing signaling 
complex). At the DISC the initiator caspases get active, which is in type I cells 
sufficient to initiate apoptosis directly via the induction of downstream effector 
caspases like caspase-3 and -7. (19) 
In type II cells the amount of active caspase-8 is not enough, so an amplification of 
the apoptotic signal via the mitochondria takes place. This crosstalk is mediated by 
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the cleavage of Bid into truncated Bid (tBid) by active caspase-8. Subsequently tBid 
translocates to the mitochondria and induces the release of apoptotic proteins like 
cytochrome c (41). 
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Figure I.7 The extrinsic apoptotic pathway 
On binding of CD95 ligand to its receptor CD95, trimerization takes place and FADD is recruited to the 
cytosolic domain via interaction with the death domain (DD). Caspase-8 binds to the complex thus 
forming the death inducing signaling complex (DISC), where it is activated. An amplification of the 
apoptotic signal is possible upon caspase-8 mediated cleavage of Bid, which translocates to 
mitochondria. 
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5.3 INTRINSIC PATHWAY 
 
Mitochondria, the main energy producers of the cell, are essential for maintaining 
cellular life and play a major role in the apoptotic process at the same time. Besides 
amplifying the extrinsic apoptotic pathway, mitochondria are the central organelles 
involved in the propagation of death signals originating from inside the cell. Such 
signals can be for example DNA-damage, oxidative stress or signals induced by 
chemotherapeutic drugs. The central event of intrinsic apoptosis induction is the 
mitochondrial membrane permeabilization (MMP) of the outer (OMM) and the inner 
(IMM) mitochondrial membrane. MMP causes the dissipation of the mitochondrial 
membrane potential (∆ψm), which is required for mitochondrial functions as ion 
transport or energy conservation. When outer membrane integrity is lost proapoptotic 
proteins from the mitochondrial inter-membrane space are released into cytosol and 
either activate caspases or act in a caspase-independent manner leading to cell 
death. Cytochrome c, Smac/Diablo (second mitochondria derived activator of 
caspases / direct IAP binding protein with low pI), Omi/HtrA2 (high temperature 
requirement protein A2), AIF (apoptosis inducing factor) and EndoG (endonuclease 
G) belong to these apoptotic factors (42, 43). 
AIF translocates from mitochondria into the nucleus and causes caspase-
independent cell death. It induces chromatin condensation and high molecular weight 
DNA fragmentation. AIF is a flavoprotein with dual roles in life and death since 
besides its role in apoptosis its participation in the formation of the respiratory 
complex I was shown. EndoG also translocates to the nucleus and mediates 
internucleosomal DNA-fragmentation (44).  
Cytochrome c is involved in electron transport and induces upon apoptotic stimuli the 
energy-dependent (ATP/dATP) formation of the apoptosome (Figure I.8). This 
oligomeric complex consists of the protein Apaf-1 (apoptotic protease activating 
factor 1) whose conformation is changed after binding to cytochrome c, ATP/dATP 
and procaspase-9. In the apoptosome complex caspase-9 is activated and initiates 
the caspase cascade, finally leading to cell death (19, 45). 
For the prevention of accidental caspase activation there is a negative regulatory 
mechanism by the inhibitors of apoptosis proteins (IAPs) (see I.5.1.3). These in turn 
are inactivated by Smac (see I.5.3.1) and Omi/HtrA2. Omi is a serine protease that 
has been reported to cleave cIAPs and to participate in caspase-independent 
apoptosis (40, 46, 47, 48). 
  
I INTRODUCTION 
 
16 
Apoptotic stimulus
MITOCHONDRIA
Cyt c
Procaspase-9
CARD
Apaf-1
ATP
Active
caspase-9
Effector caspases
Smac
IAPs
CARD
Bcl-2
Bcl-2
BakBak
Bid, Bax
AIF,EndoG,
Omi
Apoptosome
CASPASE-INDEPENDENT
CELL DEATH
 
 
Figure I.8 The intrinsic apoptotic pathway 
Mitochondria are the central organelles in the intrinsic apoptosis pathway. Upon many different stimuli 
like chemotherapeutic drugs, the mitochondria membrane is permeabilized and proapoptotic proteins 
are released into cytosol. A complex is formed consisting of cytochrome c, Apaf-1 and procaspase-9, 
where this caspase is activated and initiates the activation of effector caspases. Smac abolishes the 
negative regulation on caspases by IAP. AIF, Omi and EndoG are supposed to induce caspase-
independent cell death. Bcl-2 family proteins (e.g. Bax, Bid) regulate the intrinsic pathway. 
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5.3.1 SMAC 
 
Smac is the best known antagonist of the IAP family and reactivates processed 
initiator as well as effector caspases through distinct mechanisms, although both 
require physical interaction with IAPs. Smac is a constitutively expressed protein 
located in inter-membrane space. Its N-terminal 55 residues encode a mitochondria-
targeting sequence, which is proteolytically removed to generate the 23 kDa mature 
Smac on entry into the mitochondria. This cleavage results in the exposure of four 
hydrophobic amino acids (Ala-Val-Pro-Ile), the tetrapeptide IAP binding motif at the 
N-terminus (30). 
Caspase-9 contains a similar internal IAP binding tetrapeptide motif (Ala-Thr-Pro-
Phe), which is exposed after activation (proteolytic cleavage). This leads to the 
recruitment of XIAP to active caspase-9, thus inhibiting the caspase. Smac binds via 
its IAP binding motif to a highly conserved surface groove on the BIR3 domain of 
XIAP and competitively displaces the bound caspase-9, thus reactivating it (Figure 
I.9).  
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Figure I.9 Simplified illustration of removal of IAP-mediated caspase-inhibition by Smac 
Smac can bind various IAPs through its N-terminal tetrapeptide binding motif. In case of initiator 
caspase-9, which has a similar IAP binding motif, active caspase-9 is displaced competitively with 
Smac from XIAP. The inhibition of effector caspases by XIAP is abolished by sterical reasons after 
binding of Smac to BIR2 of IAPs. 
 
Smac plays a less immediate role in removing the IAP-mediated inhibition of effector 
caspases, since the binding site of the IAP binding motif of Smac maps to BIR2 and 
BIR3, but the IAP fragment responsible for inhibiting caspase-3 and -7 is the linker 
between the BIR1 and BIR2 domain of XIAP. Although the mechanism is not fully 
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understood, modeling studies suggest, that steric clashes preclude the simultaneous 
binding of BIR2 to effector caspases, once Smac has bound to it (30, 34, 49). 
 
5.3.2 APOPTOSIS REGULATION BY THE BCL-2 PROTEIN FAMILY 
 
The Bcl-2 (B cell lymphoma) family is an evolutionary conserved group of proteins, 
critically involved in the regulation of the release of apoptogenic factors from 
mitochondria in the intrinsic apoptosis pathway. On the basis of functional and 
structural criteria the Bcl-2 proteins can be divided in three groups (Figure I.10).  
The first group contains antiapoptotic proteins characterized by four Bcl-2 homology 
(BH) domains, called BH1 – BH4. Most of these proteins possess a hydrophobic tail, 
which allows the attachment to membranes of organelles like mitochondria. Bcl-2 and 
Bcl-xL as representatives of this group prevent the release of apoptogenic factors 
from mitochondria and therefore protect against outer membrane permeabilization by 
a not fully understood mechanism (50, 51). 
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Figure I.10 Bcl-2 family members (modified from 40) 
On structural and functional basis Bcl-2 proteins are divided into three groups. Group I is 
characterized by 4 BH (Bcl-2 homology) domains, a membrane anchoring tail (Transmembrane) and 
antiapoptotic function. Group II consists of proapoptotic members like Bax and Bak. The third group 
has just one BH domain and regulates the function of group I and II. 
 
Group II includes e.g. Bax and Bak, proapoptotic members which are structurally 
similar to group I but lacking the BH4 domain. Bax is loosely attached to the outer 
membrane or sequestered in cytosol, whereas Bak has an anchor that attaches it to 
the mitochondrial outer membrane in a complex with the VDAC (voltage-dependent 
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anion channel). Upon a death stimulus Bak and Bax undergo a conformational 
change, oligomerize and induce the formation of a pore in the OMM through which 
e.g. cytochrome c and Smac are released. Another model proposes that Bax targets 
one or more components of the permeability transition in the IMM (40, 52). 
Group III, also known as BH3-only proteins, has many members whose common 
feature is the presence of a single BH3 domain. These proteins fulfill their 
proapoptotic function either by activating proapoptotic proteins like Bax or by 
inhibiting antiapoptotic Bcl-2 proteins. Bid for example is thought to induce the 
conformational change in Bax/Bak, which leads to insertion in the OMM. 
 
5.4 PIDDosome 
 
Recruitment to large macromolecular complexes is a critical step in activating initiator 
caspases. This is well established for caspase-8, which is recruited to the death 
inducing signaling complex (extrinsic pathway, see I.5.2) and for caspase-9, which is 
activated in the apoptosome (intrinsic pathway, see I.5.3) complex. Besides these 
two complexes the inflammasome is known with the inflammatory initiator caspases 
-1 and -5 as constitituents (53).  
Caspase-2 is one of the most conserved caspases and shares the commonness of 
the initiator caspases named above: it contains a CARD, the responsible structural 
element for recruitment to the described protein complexes.  
 
CARD CARD DD DD
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Figure I.11 The PIDDosome  
Caspase-2 can be activated via the PIDDosome. This complex consists of procaspase-2, the adaptor 
protein RAIDD and the p53-inducible protein with a death domain (PIDD). Procaspase-2 and RAIDD 
can interact via their caspase-recruitment domain (CARD). RAIDD interacts with PIDD via a death 
domain (DD). PIDD also contains LRR (leucine rich repeats), a protein interaction motif found in 
various proteins with diverse function. 
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Indeed, a complex for the activation of caspase-2 was recently described as well. 
The so called PIDDosome (Figure I.11) is a large protein complex with a molecular 
weight in excess of 670 kDa. It consists of the adaptor protein RAIDD (RIP-
associated ICH1/CED3-homologous protein with a death domain) and PIDD (p53-
induced protein with a death domain). RAIDD contains a CARD through which it can 
bind caspase-2 and a DD that allows interaction with PIDD (54, 55, 56).  
Besides the death domain PIDD contains N-terminal leucine-rich repeats (LRRs), 
protein interaction motifs probably for recognizing signals of unknown nature (53, 56, 
57). 
Activation of the PIDDosome is described to sensitize cells to genotoxic stress, but in 
addition to DNA-damage cell lysis under hypotonic conditions initiates the assembly 
(56).  
At present, it is unclear whether additional factors are involved in the assembly of the 
PIDDosome. 
 
5.5 APOPTOSIS DEREGULATION – TARGETS FOR DRUG 
DISCOVERY 
 
Deregulation of apoptosis can disrupt the balance between proliferation and cell 
death and can lead to diseases as cancer. In many cancers, proapoptotic proteins 
have inactivating mutations or are deleted or the expression of antiapoptotic proteins 
is upregulated. Cancers that possess alterations in proteins involved in the extrinsic 
or intrinsic cell death signaling are often resistant to chemotherapy. The metastatic 
melanoma for instance still has poor prognosis with response rates ranging from 10 
to 25% and a mean survival of 8 month for single dacarbazine treatment. Neither 
combination of dacarbazine with other drugs nor immunotherapy could effectively 
improve the therapy outcome. Therefore, new strategies to restore programmed cell 
death are needed and might be effective against many cancers. One promising 
approach is the investigation of the altered signal network in cancer growth regulation 
in order to act with specificity at molecular level. At present, agonistic antibodies 
against TRAIL receptors or antisense oligonucleotides targeting the antiapoptotic 
protein Bcl-2 are in clinical trials. Inhibitors of the antiapoptotic IAP family are under 
preclinical examination (58, 59, 60).  
In this respect STAT3 (signal transducer and activator of transcription) is – among 
many others – a very interesting therapeutic target, since it joins numerous 
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oncogenic signaling pathways and is constitutively activated at 50 – 90% frequency 
in diverse human cancers, whereas it is tightly controlled and transiently activated in 
non-transformed cells (61). Persistent STAT3 activity leads to profound changes in 
gene expression patterns altering cell survival and proliferation, angiogenesis and 
metastasis and immune evasion (61). 
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Figure I.12 Consequences of persistent STAT3 activity 
Constitutive activity of STAT3 leads to alterations in the regulation of cell survival and proliferation. 
↑ = upregulation; ↓ = downregulation. 
 
The first anti-apoptotic factor found to be regulated by STAT3 was Bcl-xL, but since 
then many other proteins, e.g. survivin or cyclin D1, that are crucial for tumor cell 
proliferation and survival have been found to be controlled by this transcription factor 
(Figure I.12). First studies have shown that interruption of survivin activity via 
phosphorylation mutants or inhibition of protein synthesis via antisense 
oligonucleotides leads to caspase-dependent and caspase-independent PCD (62, 
63, 64). 
Survivin is ubiquitously expressed during development but is absent in most adult 
tissues. In contrast, it is highly expressed in cancer cells and associated with 
decreased patient survival, making survivin as well as STAT3 attractive diagnostic 
and therapeutic targets (64). 
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II MATERIALS AND METHODS 
1 MATERIALS 
1.1 CEPHALOSTATIN 
 
Cephalostatin 2, cephalostatin 10 and cephalostatin 12 were isolated as described in 
(6, 11, 10). The substances were kindly provided by Prof. G. R. Pettit (Cancer 
Research Institute, Arizona State University, Tempe, USA). The 10 mM stock 
solutions prepared in DMSO were stored at -20°C. 
 
1.2 REAGENTS 
 
 
Reagent Company 
Complete Roche, Mannheim, 
Germany 
DMEM PAN Biotech, Aidenbach, 
Germany 
DMSO Roth GmbH, Karlsruhe, 
Germany 
Etoposide Calbiochem, Schwalbach, 
Germany 
FCS gold  PAN Biotech, Aidenbach, 
Germany 
G418 sulfate PAA Laboratories, Cölbe, 
Germany 
Hoechst 33342 Sigma, Taufkirchen, 
Germany 
McCoy´s 5a PAN Biotech, Aidenbach, 
Germany 
Mitotracker Red Molecular Probes, 
Karlsruhe, Germany 
MTT  Sigma, Taufkirchen, 
Germany 
Paclitaxel Sigma, Taufkirchen, 
Germany 
Reagent Company 
Polyacrylamide Roth GmbH, Karlsruhe, 
Germany 
Propidium iodide  Sigma, Taufkirchen, 
Germany 
Puromycin PAA Laboratories, 
Cölbe, Germany 
Q-VD-OPh Calbiochem, 
Schwalbach, Germany 
RPMI 1640  PAN Biotech, 
Aidenbach, Germany 
SP600125 Calbiochem, 
Schwalbach, Germany 
Staurosporine  Calbiochem, 
Schwalbach, Germany 
Thapsigargin Sigma, Taufkirchen, 
Germany 
zVAD-fmk Calbiochem, 
Schwalbach, Germany 
zVDVAD MBL, Woburn, USA 
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2 CELL CULTURE 
2.1 CELL LINES 
2.1.1 HUMAN LEUKEMIA JURKAT T CELL LINES 
 
All human leukemia Jurkat T cell lines were cultivated in RPMI 1640 containing 2 mM 
L-glutamine supplemented with 10% fetal calf serum (FCS) and 1% pyruvate.  
Caspase-9-deficient and -reconstituted Jurkat T cells (65) and Bak-deficient and 
reconstituted Jurkat T cells (courtesy of Prof. Dr. K. Schulze-Osthoff, Düsseldorf, 
Germany) were cultured in the medium described above containing heat-inactivated 
FCS.  
Jurkat cells stably overexpressing XIAP were provided by Dr. C. Duckett (University 
of Michigan). These cells were cultivated in the medium described for Jurkat T cells 
in the presence of 1 µg/ml puromycin every fifth passage. 
 
2.1.2 CARCINOMA CELL LINES 
 
The human cervix carcinoma cell line HeLa was obtained from the German Collection 
of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). The human 
melanoma cell line SK-Mel-5 was obtained from the American Type Culture 
Collection (ATCC, Manassas, USA). HeLa and SK-Mel-5 cells were cultivated in 
DMEM containing 2 mM L-glutamine supplemented with 10% fetal calf serum and 
1% pyruvate. The human ovarian cancer cell line SK-OV-3 was obtained from ATCC 
and cultivated in McCoy´s 5a supplemented with 10% fetal calf serum. MCF-7 cells 
and caspase-3 reconstituted MCF-7 cells were kindly provided by Prof. Dr. K. 
Schulze-Osthoff. MCF-7 stably transfected with either Smac-YFP or cytochrome c-
GFP (66) were provided by Prof. Dr. J.H.M. Prehn. All MCF-7 cells were grown in 
RPMI 1640 containing 2 mM L-glutamine supplemented with 10% heat-inactivated 
fetal calf serum. See Table II.1 for a summary of the used cell lines. 
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Table II.1: summary of used cell lines 
 
Jurkat T cell clones Carcinoma cell lines 
Wild type J16 HeLa 
Caspase-9-deficient cells SK-Mel-5 
Caspase-9-reconstituted cells SK-OV-3 
XIAP-overexpressing Jurkat cells MCF-7 +/- Caspase-3 
Bak-deficient cells MCF-7 smac-YFP 
Bak-reconstituted cells MCF-7 cytochrome c-GFP 
 
2.2 CULTIVATION 
 
All cell lines were cultured at 37°C and 5% CO2 in humified atmosphere. Cell density 
and viability was determined by staining with trypan blue using a VI-CELLTM cell 
viability analyzer (Beckman Coulter, Krefeld, Germany). 
The Jurkat subclones were split three times a week and diluted with prewarmed 
medium to 1 x 105 cells/ml respectively 7 x 104 cells/ml before weekends. Cell density 
never exceeded 1 x 106 cells/ml in order to maintain genetic stability. For the same 
reason cells were not used for experiments any longer after reaching passage 20. 
HeLa, SK-Mel-5, SK-OV-3 and MCF-7 cells were grown as monolayer and split when 
reaching 80 - 90% confluence. Briefly, cells were washed with prewarmed PBS (see 
below) and detached with 3 ml Trypsin/EDTA (see below) / 75 cm2 flask. After 
detaching, Trypsin/EDTA was inactivated by adding 7 ml medium and cells were 
centrifuged (180 x g, 10 min, RT). Cells were resuspended in fresh medium and 
1 - 3 x 106 cells were transferred to 75 cm2 cell culture flasks. 
 
 
PBS (pH 7.4) 
NaCl    7.2 g 
Na2HPO4  1.48 g 
KH2PO4  0.43 g 
H2O ad 1,000 ml 
Trypsin/EDTA (T/E) 
Trypsin  0.50 g 
EDTA  0.20 g 
PBS ad 1,000 ml 
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2.3 SEEDING FOR EXPERIMENTS 
 
Jurkat leukemia T cells were seeded approximately 16 h before experiments at a 
density of 0.5 x 106 cells/ml. Alternatively, cells were seeded 2-3 h before 
stimulation, with higher density (0.7 x 106 cells/ml). Cells were centrifuged 
(180 x g, 10 min, RT), resuspended in prewarmed medium and cell density was 
determined by VI-CELLTM cell viability analyzer. Cells were diluted with medium to 
the desired concentration and seeded in 24-well tissue culture plates for all 
experiments except MTT viability assay (96-well plates, see II .4) and clonal 
survival assay (6-well plates, see II .6). 
Carcinoma cell lines were detached and centrifuged as described in II2.1.2. Cell 
concentration was adjusted to 0.2-0.3 x 106 cells/ml and seeded in 12- or 24-well 
plates the day before the experiment. Before stimulating the cells medium was 
removed and replaced by fresh medium. 
 
2.4 FREEZING AND THAWING 
 
In order to preserve a sufficient stock of each cell line, long term storage took 
place in liquid nitrogen. Therefore, cells in low passages were frozen in special 
medium (Table II.2: Freezing medium), containing DMSO for avoiding cell rupture. 
Cells were centrifuged (180 x g, 10 min, 4°C) and resuspended in ice-cold freezing 
medium at a concentration of 2-3 x 106 cells/ml. 1.5 ml cell suspension was 
transferred into each cryovial and frozen at -20°C over night. Afterwards, vials 
were stored at -80°C for permanent usage or transferred into liquid nitrogen after 
two days for long term storage. 
Cells were defrosted by gently dissolving in 10 ml prewarmed medium. 
Subsequent, cells were centrifuged (180 x g, 10 min, RT) to remove DMSO and 
dead cells. After resuspension in fresh medium, cells were left to grow for at least 
five days before any experiments. 
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Table II.2: Freezing medium 
 
 HeLa Jurkat MCF-7 SK-Mel-5 SK-OV-3 
RPMI 1640 - 70% 70% - - 
DMEM 80% - - 80% - 
McCoy´s 5a - - - - 85% 
FCS gold 10% 20% 20% 10% 10% 
DMSO 10% 10% 10% 10% 5% 
 
 
3 FLOW CYTOMETRY 
 
Flow cytometry is a technology that allows the measurement of multiple physical 
characteristics of single particles at the same time. These particles, usually cells, 
are suspended in a stream of fluid and pass through a beam of light. The list of 
measurable parameters includes properties like a particle’s relative size, relative 
granularity or internal complexity and relative fluorescence intensity. Among other 
things, this method is suitable for measuring cell cycle, apoptosis, viability, protein 
expression and localization, cell surface antigens and enzymatic activity. 
 
 
Figure II.1 flow chamber of a flow cytometer (from 67) 
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The fluid stream transporting the cells should be positioned in the center of the 
laser beam to yield optimal illumination and the cells or particles should move 
through the laser beam one by one. For this reason the sample is injected into a 
stream of sheath fluid within the flow chamber, where the sheath fluid accelerates 
the particles and restricts them to the center of the sample core (see Figure II.1). 
This process is called hydrodynamic focusing. 
When particles pass the laser beam, the light is scattered and simultaneously, if 
the particles have been stained with fluorescence dyes able to absorb the laser 
light, fluorescence occurs. The scattered and fluorescent light is collected by 
lenses and forwarded to the appropriate detectors. 
Morphological parameters like the relative size and granularity of a cell influences 
the light scattering. In line with the laser beam the forward scatter (=FSC) 
proportional to cell size is measured. Light scattered perpendicular to the laser is 
called sideward scatter (SSC) and is characteristic for the internal complexity. 
Fluorescence was measured by using the appropriate filters for the respective 
fluorochromes (e.g. FL2 for detection of propidium iodide). All measurements were 
performed on a FACSCalibur (Becton Dickinson, Heidelberg, Germany), equipped 
with a 488 nm argon laser. Sheath fluid is composed as seen below (FACS 
buffer). 
 
FACS buffer (pH 7.37) 
NaCl   8.12 g 
KH2PO4  0.26 g 
Na2HPO4  2.35 g 
KCl   0.28 g 
Na2EDTA  0.36 g 
LiCl   0.43 g 
Na-azide  0.20 g 
H2O ad 1,000 ml 
 
3.1 NICOLETTI ASSAY 
 
A simple and rapid method for quantification of apoptosis is the measurement of 
DNA fragmentation, a characteristic event caused by the activation of 
endonucleases. According to the method of Nicoletti et al. (68) cells are 
permeabilized in a hypotonic buffer (HFS buffer, hypotonic fluorochrome solution), 
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which contains propidium iodide for staining the DNA. The resulting red 
fluorescence is measured by flow cytometry. Figure II.2 shows a characteristic 
histogram of untreated control cells after staining with propidium iodide. 
Fluorescence intensity is proportional to DNA content resulting in a peak 
containing 2n DNA content (G0/G1), whereas cells in G2/M phase emit higher 
fluorescence due to 4n DNA content. Upon eluting the low molecular weight 
fragments of apoptotic cells by the hypotonic buffer less dye is taken up and the 
resulting hypodiploid region left to the G0/G1 peak is considered apoptotic (sub 
G1). 
G1
sub G1
G2
S
 
Figure II.2 Histogram of untreated PI-stained cells 
Jurkat cells were permeabilized and stained with propidium iodide (PI). A typical histogram of 
untreated cells is shown with different peaks representing cell cycle distribution. The region left to 
the G1 peak is considered apoptotic (sub G1). 
 
Protocol: Jurkat cells and adherent cell lines were seeded as described in chapter 
II2.3 and either left untreated or stimulated with the required substances. After 
different incubation times cells were harvested by centrifugation (600 x g, 10 min, 
4°C) and washed once with cold PBS. Cells were incubated in 250 µl (Jurkat cells) 
or 500 µl (adherent cell lines) HFS buffer (see below) overnight at 4°C and 
analyzed by flow cytometry. The percentage of sub G1 region was determined as a 
parameter of apoptotic cells. 
 
HFS buffer 
Sodium citrate  0.1% (w/v) 
Triton X-100 0.1%  (v/v) 
PBS ad 1,000 ml  
Shortly before use, add 50 µg/ml propidium iodide. 
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3.2 PHOSPHATIDYLSERINE TRANSLOCATION 
 
An early event in apoptosis is the loss of cell membrane asymmetry. In healthy 
cells, the phospholipid phosphatidylserine (PS) is located on the cytoplasmic side 
of the membrane. Upon apoptotic stimuli it translocates to the outer leaflet of the 
cell membrane. The annexin V assay makes use of this exposure of PS for the 
detection of cells in early or immediate apoptosis, even before events like DNA 
fragmentation can be measured. Annexin V is a small Ca2+ dependent protein with 
a high and selective affinity for PS. It can be tagged with FITC without 
compromising its binding properties to PS thus enabling the marked cells to be 
analyzed by flow cytometry. An additional staining with PI opens the opportunity to 
distinguish between live cells (Annexin V negative, PI negative), apoptotic cells 
(Annexin V positive, PI negative) and necrotic cells (Annexin V positive, PI 
positive).  
Protocol: Phosphatidylserine translocation was analyzed by the Annexin V-FITC 
Detection Kit (BenderMed Systems, Vienna, Austria) according to the 
manufacturer’s instructions. Briefly, cells were either left untreated or stimulated 
with the required substances for different periods of time and collected by 
centrifugation (600 x g, 4°C, 10 min). They were washed once with cold PBS, 
resuspended in 1x binding buffer and incubated with Annexin V-FITC solution for 
15 min at room temperature. After another centrifugation step (600 x g, 4°C, 
10 min), the pellet was resuspended and PI solution was added. The probes were 
immediately analyzed by FACS. Only Annexin V positive and PI negative cells 
were considered apoptotic. 
 
 
4 MTT VIABILITY ASSAY 
 
The mitochondrial respiratory activity is a parameter for cell viability. Though, a 
method for cytotoxicity determination of a substance is to measure this activity by 
the MTT assay. This colorimetric assay uses the tetrazolium salt MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide). It is based on the 
reduction of MTT by enzymes of the mitochondrial electron transport assembly, 
leading to the formation of a blue formazan derivative. The reduction is 
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proportional to the activity of the assembly and thus to the vitality of the cells. The 
absorption of the formazans can be measured at 550 nm in a spectrophotometer.  
Protocol: Cells were seeded at a concentration of 7 x 105 (Jurkat cells) or 
0.15 x 105 (SK-Mel-5) cells/ml in a 96-well plate (100 µl per well) the day before 
stimulation. After stimulation 10 µl of MTT solution (stock solution: 5 mg/ml in PBS, 
sterile filtered and kept in aliquots at –20°C) was added to each well and incubated 
at 37°C for 60 minutes. Afterwards, cells were lysed by adding 190 µl DMSO to 
each well and shaking the plates in the dark for another hour. Finally, the 
absorption of the solubilized formazan crystals was measured at 550 nm in an 
ELISA plate reader (SLT spectra, SLT Labinstruments, Crailsheim, Germany). 
 
 
5 MICROSCOPY 
5.1 LIGHT MICROSCOPY 
 
The characteristic morphological changes of apoptosis as well as other forms of 
programmed cell death, such as shrinking, swelling or formation of apoptotic 
bodies can be easily detected by light microscopy. 
Cells were left untreated or stimulated with the required substances for different 
periods of time. Cells were viewed with a Zeiss Axiovert 25 microscope (Zeiss, 
Oberkochen, Germany) at 40 x magnification and images were obtained with a 
connected reflex camera. 
 
5.2 FLUORESCENCE MICROSCOPY 
 
A characteristic feature of an apoptotic cell is condensation of DNA followed by its 
fragmentation. Vital staining of DNA with Hoechst 33342 allows visualization of 
DNA changes in a fluorescence microscope. The dye is cell permeable and 
intercalates in the DNA due to its planar structure. Healthy cells emit only weak 
blue fluorescence since the DNA is distributed evenly in the nucleus. The nucleus 
of apoptotic cells is smaller in size and due to the condensed DNA shows a strong 
blue signal.  
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Protocol: Cells were either left untreated or stimulated with cephalostatin for 
various periods of time. 10 µl of Hoechst solution (0.1 mg/ml in H2O) were added 
to each well and the plate was incubated at 37°C for approximately 5 min. 
Subsequently, pictures were taken with a Zeiss Axiovert 25 microscope (Zeiss, 
Jena, Germany) and connected camera. 
 
5.3 CONFOCAL MICROSCOPY 
 
In a conventional light microscope all object points are illuminated parallel, 
whereas the organism in a confocal LSM is irradiated in a point wise manner. The 
out of focus information is eliminated by a pinhole, allowing high-quality images 
with a maximum resolution. Confocal imaging enables three-dimensional studies 
of thick specimens and colocalization of signals from different fluorochromes. 
 Protocol: for the visualization of Smac and cytochrome c release a LSM 510 Meta 
(Zeiss, Oberkochen, Germany) was used. MCF-7 cells stably expressing either 
cytochrome c-GFP or Smac-YFP (66) were seeded on glass coverslips in 24-well 
plates and grown overnight. Cells were stimulated with 1 µM cephalostatin or 2 µM 
staurosporine. 1 hour prior to the end of stimulation cells were stained with 100 nM 
Red 580 (Molecular Probes, Karlsruhe, Germany). Cells were washed 3 times with 
PBS and fixed with 3% paraformaldehyde in PBS for 15 min at room temperature 
and washed again three times with PBS. Glass coverslips were then covered with 
a droplet of fluorescent mounting medium and mounted on a microscope slide. 
 
 
6 CLONOGENIC ASSAY 
 
Clonogenic assay or colony formation assay is an in vitro long term cell survival 
assay to determine the effectiveness of cytotoxic agents. It is based on the ability 
of a single cell to grow into a colony. The assay essentially tests every cell in the 
population for its ability to undergo “unlimited” division.  
Protocol: SK-Mel-5 cells were seeded as described in II.2.3 and treated with 
50 nM cephalostatin or 50 nM taxol for 2 hours. Afterwards cells were detached 
and washed with PBS to remove eventually remaining substances. Cell count was 
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determined and 1 x 104 SK-Mel-5 cells were seeded in 6-well plates. Cells were 
left to grow for 8 days and colonies were stained with crystal violet. Since SK-Mel-
5 cells don’t posses the ability to form colonies, but grow as loosely spreaded 
network, instead of counting the colonies crystal violet was solved and absorption 
at 550 nm was measured. Untreated control cells were set 100% viability. 
 
 
7 WESTERN BLOT 
 
Western blot is a method to detect specific proteins present in a given sample, for 
example a cell lysate. Denaturized proteins are first separated by mass using gel 
electrophoresis and then transferred onto a membrane. Afterwards proteins can 
be visualized by immunodetection using a specific antibody. 
 
7.1 SAMPLE PREPARATION 
7.1.1 WHOLE CELL LYSATES 
 
 
General lysis buffer 
Tris-HCl, pH 7.5              30 mM 
NaCl             150 mM 
EDTA                 2 mM 
Triton X-100                    1% 
CompleteTM 
 
Sample buffer (5x) 
3.125 M Tris-HCl, pH 6.8  100 µl 
Glycerol    500 µl 
SDS 20%   250 µl 
DTT 16%   125 µl 
Pyronin Y 5%   5 µl 
Lysis buffer for phosphorylated proteins 
Tris-HCl, pH 7.5       20 mM 
NaCl      137 mM 
Na4P2O7            2 mM 
EDTA          2 mM 
C3H7Na2O6P (Na glycerolphosphate)     20 mM 
NaF        10 mM 
Na3VO4             2 mM 
PMSF          1 mM 
Triton X-100             1% 
Glycerol            10% 
CompleteTM 
H2O ad 1 ml 
 
 
II MATERIALS AND METHODS 
 
  33   
Protocol: Jurkat cells or adherent cell lines were seeded (see II.2.3) and left 
untreated or stimulated with cephalostatin 2 or the respective positive controls. 
After incubation cells were harvested by centrifugation (1500 rpm, 10 min, 4°C) 
and washed once with cold PBS. The adherent cell lines had to be detached by 
Trypsin/EDTA and were also centrifuged and washed. Pellets were resuspended 
in the appropriate lysis buffer (100 µl for three wells) and incubated on ice for 30 
min or stored at -20°C. Subsequently, lysates were centrifuged at 10,000 x g, 4°C 
for 10 min. Supernatants were transferred to new tubes and protein concentration 
was determined by the Bradford method as described in IV.7.2. Lysates were 
diluted 1:5 with 5 x sample buffer and boiled at 95°C for 5 min. Afterwards, 
samples were stored at -20°C or used immediately for western blot analysis. 
PMSF, Na3VO4 and Complete™ were added to the lysis buffers immediately 
before use. 
 
7.1.2 CYTOSOLIC AND MITOCHONDRIA CONTAINING FRACTIONS  
 
In apoptosis, molecules like cytochrome c and Smac normally localized in the 
intermembrane space of mitochondria are released into the cytosol. There they 
are part of activation complexes for caspases or they translocate into the nucleus 
where they participate in DNA fragmentation (Endonuclease G, AIF). For 
analyzing the release of these factors, the cytosol has to be separated from the 
mitochondria. This is accomplished by a permeabilization buffer containing a low 
concentration of digitonin which forms complexes with cholesterol in the cell 
membrane. Thus, small pores develop through which the cytosol is eluted into the 
iso-osmotic buffer while organelles are retained inside the cell. The protocol was 
carried out as described previously (15). 
 
Permeabilization buffer (pH 7.2) 
Mannitol       210 mM 
Sucrose          70 mM 
Hepes pH 7.2         10 mM 
EGTA          0.2 mM 
Succinate            5 mM 
BSA  0.15% (w/v) 
Digitonin      60 µg/ml 
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Protocol: Cells were seeded and stimulated as for whole cell lysate preparation. 
Three wells for each probe were pooled and centrifuged at 360 x g, 4°C for 
10 min. The supernatant was discarded thoroughly. After washing the cells with 
cold PBS, the pellets were resuspended carefully in 100 µl permeabilization buffer 
and incubated on ice for 20 min. The cytosolic fraction was obtained by 
centrifugation of the cell suspension at 360 x g (4°C, 10 min) and the supernatant 
was cleared of any remaining cell fragments at 13,000 x g (4°C, 10 min). The 
pellet of the first centrifugation after permeabilization containing the mitochondria, 
the other organelles and the membranes was resuspended in 0.1% Triton-X 100 in 
PBS (100 µl) and lysed for 15 min on ice. The supernatant of a subsequent 
centrifugation step (13,000 x g, 4°C, 10 min) constitutes the mitochondria-enriched 
fraction. Protein determination was carried out with the Bradford method. The 
probes were diluted with 5x sample buffer and boiled at 95°C for 5 min. 
Afterwards, they were separated immediately by SDS-PAGE or stored at -20°C. 
 
7.2 PROTEIN QUANTIFICATION 
 
The protein content in samples was quantified by the Bradford (69) method. This 
method is based upon the binding of the dye Coomassie Brilliant Blue G-250 to 
hydrophobic parts of proteins. After binding to proteins, the absorption maximum 
of this dye shifts from 465 to 595 nm and absorbance is measured at 595 nm.  
Protocol: 10 µl of a calibration curve containing increasing concentrations of BSA 
in H2O (0 up to 25 mg/ml BSA) and 10 µl of 1:10 in H2O diluted cell lysates were 
incubated with 190 µl of Bradford solution (Bio-Rad, Munich, Germany, diluted 1:5 
in H2O) in 96-well plates for 5-10 min and absorbance of samples at 592 nm was 
measured in a microplate absorbance reader (Sunrise™, Tecan, Crailsheim, 
Germany). Before electrophoresis, the required volumes of 1x sample buffer were 
added to the protein solutions in order to achieve the same protein concentration 
in all samples. 
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7.3 SDS-PAGE 
 
Equal amounts of the above described protein samples are separated by 
discontinuous denaturizing SDS-PAGE according to Laemmli (70). The anionic 
detergent sodium dodecyl sulphate (SDS) is used to solubilize the proteins upon 
binding to hydrophobic parts. Thereby protein secondary and tertiary structures 
are destroyed. Further unfolding is achieved by the reducing agent dithiothreitol 
(DTT), which cleaves disulfide bonds. Proteins get highly negative charged by 
SDS and are though drawn towards the anode in an electric field. Therefore, the 
proteins are separated solely by their size in the polyacrylamide gel. This 
discontinuous electrophoresis system consists out of two layers: the stacking gel, 
where the proteins are concentrated and the separating gel, where the proteins 
are separated.  
 
Stacking gel 
PAA solution 30%     1.7 ml 
1.25M Tris-HCl, pH 6.8        1 ml 
SDS 10%      100 µl 
H2O       7.0 ml 
TEMED         20 µl 
APS (10%)      100 µl 
 
Electrophoresis buffer 
Tris Base                       3 g 
Glycine                   14.4 g 
SDS                        1 g 
H2O ad 1,000 ml 
 
 
Separating gel (10%) 
PAA solution 30%                5 ml 
1.5M Tris-HCl, pH 8.8           3.75 ml 
SDS 10%              150 µl 
H2O               6.1 ml 
TEMED                 15 µl 
APS (10%)                75 µl 
Table II.3 PAA-concentration in the separating gel 
 
Protein Acrylamide concentration 
PARP, PIDD 7,5 % 
caspase-9, AIF, STAT3 10 % 
caspase-2, caspase-4, caspase-3 12 % 
Smac, cytochrome c, RAIDD, survivin 15 % 
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Depending on the molecular weight of the investigated proteins the polyacrylamide 
(PAA) (RotiphoreseTM Gel 30, Roth, Karlsruhe, Germany) concentration was 
adjusted to yield an optimal separation (see Table II.3 PAA-concentration in the 
separating gel). To determine the molecular weight, samples are compared with 
prestained broad range molecular weight markers (precision All Blue®, Bio-Rad, 
Munich, Germany; MBI-Fermentas, Germany). 
Electrophoresis was performed using a vertical Mini Protean III system (Bio-Rad, 
Munich, Germany) connected to a power supply (Biometra, Göttingen, Germany). 
Electrophoresis was run at 100 V for 21 min for stacking of proteins and at 200 V 
for 35-40 min for the separation of proteins. 
 
7.4 WESTERN BLOTTING AND DETECTION 
 
Subsequent to electrophoresis, proteins are transferred from the gel onto blotting 
membranes, which are incubated with specific antibodies. Afterwards proteins 
were visualized by chemiluminescence.  
Tank blot technique was used to carry out western blot analysis. Nitrocellulose 
membranes (Hybond™-ECL™, Amersham Biosciences, Freiburg, Germany) were 
activated by soaking in freshly prepared 1x blotting buffer for at least 15 minutes. 
Afterwards, transfer sandwiches were assembled as follows: 
 
sandwich holder cathode side 
wetted pad 
soaked blotting paper 
gel 
membrane  
soaked blotting paper 
wetted pad 
sandwich holder anode side 
 
Sandwiches were inserted in a transfer device (Mini Trans-Blot®, Bio-Rad, Munich, 
Germany), the electrophoresis chamber was filled up with 1 x buffer and transfer 
was performed at 4 °C at 100 V for 90 min or at 23 V overnight, with magnetic 
stirring. 
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Blotting buffer (5x) stock solution 
Tris Base  15.2 g 
Glycine   72.9 g 
H2O ad 1,000 ml 
Blotting buffer (1x) 
5x blotting buffer  200 ml 
Methanol  200 ml 
H2O ad 1,000 ml
 
 
After transfer, membranes were blocked in 5% non-fat dry milk in Tris-buffered 
saline with Tween (TBS-T) for 1 h at room temperature. After a short washing in 
TBS-T, membranes were incubated in the respective primary antibody solutions 
(Table II.4 Primary antibodies) overnight at 4°C or for 2 h at RT with gently 
shaking. 
After 3 x 10 minutes washing steps in TBS-T, membranes were incubated with 
secondary antibodies (see Table II.5) conjugated to horseradish peroxidase for 1 h 
at room temperature or overnight at 4°C. After washing the membrane as 
described above, proteins of interest were visualized using the ECL Plus™ 
Western Blotting detection reagent (Amersham Biosciences, Freiburg, Germany). 
Membranes were exposed to X-ray film for the appropriate time periods and 
subsequently developed in a tabletop film processor (Curix 60, Agfa, Cologne, 
Germany). 
 
TBS-T (pH 8.0) 
Tris base      3 g 
NaCl  11.1 g 
Tween 20    1 ml 
H2O ad 1,000 ml 
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Table II.4 Primary antibodies 
 
primary antibody isotype  dilution company 
AIF rabbit IgG 1:1,000 Chemicon, Hofheim, Germany 
caspase-2 mouse IgG1 1:1,000 BD Biosciences, Heidelberg, Germany 
caspase-3 mouse IgG2a 1:1,000 BD Biosciences, Heidelberg, Germany 
caspase-4 mouse IgG1 1:1,000 MBL, Woburn, USA 
caspase-9 rabbit IgG 1:1,000 Cell Signaling, Frankfurt, Germany 
cytochrome c mouse IgG1 1:1,000 Cell Signaling, Frankfurt, Germany 
PARP mouse IgG1 1:100 Calbiochem, Bad Soden, Germany 
PIDD rabbit IgG 1:1,000 Alexis 
RAIDD mouse IgG1 1:1,000 MBL, Woburn, USA 
Smac rabbit IgG 1:500 Biozol, Eching, Germany 
STAT3 rabbit IgG 1:1,000 Cell signaling, Frankfurt, Germany 
pStat3 Ser 727 rabbit IgG 1:1,000 Cell signaling, Frankfurt, Germany 
pStat3 Tyr 705 mouse IGg1 1:1,000 Cell signaling, Frankfurt, Germany 
survivin rabbit IgG 1:1,000 Cell signaling, Frankfurt, Germany 
Table II.5 Secondary antibodies 
secondary antibody dilution company 
goat anti mouse IgG1: HRP 1:1,000 Biozol, Eching, Germany 
goat anti rabbit :HRP 1:10,000 Dianova, Hamburg, Germany 
goat anti mouse IgG2A :HRP 1:1,000 Biozol, Eching, Germany 
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7.5 STAINING OF GELS AND MEMBRANES 
 
Equal protein loading and blotting of samples was checked by staining of gels with 
Coomassie Brilliant blue as well as staining of membranes after Western blot 
experiments with Ponceau S. In contrast to Coomassie staining, Ponceau S stain 
is reversible. 
After tank blot procedure gels were shaken and stained with Coomassie blue 
solution for 10 min at room temperature. Next gels were washed several times in 
destaining solution until the proteins appeared as blue bands and could be 
distinguished against the background. 
 
Coomassie staining solution 
Coomassie Blue        3 g 
Glacial acetic acid 100 ml 
Ethanol   450 ml 
H2O ad 1,000 ml 
Destaining solution 
Glacial acetic acid 100 ml 
Ethanol   300 ml 
H2O ad 1,000 ml
 
Membranes were stained in Ponceau staining solution (0.2% Ponceau S in 5% 
acetic acid) for 5 minutes. Afterwards, membranes were washed in H2O until the 
background disappeared. To remove the Ponceau staining completely, membrane 
was washed in TBS-T. 
 
 
8 IMMUNOPRECIPITATION 
 
Immunoprecipitation is a method used for the enrichment of the proteins of 
interest. Therefore a specific antibody is incubated with a cell lysate to form the 
antigen-antibody complex. This complex can be precipitated e.g. by addition of 
Protein G or Protein A, which has high affinity to the Fc-part of immunoglobulins. 
After dissociating and denaturizing the proteins by boiling, the precipitate can be 
investigated by Western blot analysis. 
Protocol: Jurkat cells were seeded as described in II.2.3 and stimulated for 1 h 
with 50 nM cephalostatin 2, 2 µM etoposide or 3 µM thapsigargin. Afterwards, cells 
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were lysed in general lysis buffer and the amount of protein was determined. 
Simultaneously, 50 µl Protein A Sepharose Beads (Sigma) for each sample were 
centrifuged, washed and resuspended in lysis buffer. 2.5 µl of the respective 
antibody was added per 50 µl Protein A solution and gently inverted at 4°C for 
approximately 3 h. After that, the Protein A-antibody solution was centrifuged 
(3,000 x g, 2 minutes, 4°C) and carefully washed three times with lysis buffer. 
300 – 400 µg protein were filled up to a final volume of 250 µl with lysis buffer and 
added to the bead solution. In order to allow the immune complexes to form, the 
samples were gently shaken over night at 4°C by end over end rocking. In the next 
step the precipitates were harvested by centrifugation and 40 µl of the supernatant 
were kept as binding control. The remaining pellet was carefully washed three 
times with 500 µl lysis buffer. After completely removing the last wash solution, 
sample was mixed with 2-mercaptoethanol containing Laemmli sample buffer, 
boiled at 95°C for 5 minutes and analyzed by Western blot. 
 
 
9 siRNA 
 
RNA interference (RNAi) is a widespread phenomenon found in fungi, plants and 
animals.  
dsRNA
DICER
small RNA duplex
RISC mRNA destruction
 
 
Figure II.3 short interfering RNA (modified from 71) 
RNA interference is an ancient defense mechanism against foreign double stranded (ds) RNA. 21-
23 nucleotides long small interfering (si) RNAs are cleaved by DICER out of long dsRNAs. These 
siRNAs (small RNA duplex) can be chemically synthesized for laboratory use. The antisense 
strand is guided to the RNA induced silencing complex (RISC), where the corresponding mRNA 
strand is bound and degraded, leading to gene silencing. 
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It concerns about double stranded (ds) RNAs that trigger specific gene silencing. 
Long dsRNA molecules are converted by an enzyme called DICER into smaller 
(21-23 nt) RNAs. The antisense short RNAs (siRNA) are incorporated into a RNA 
induced silencing complex (RISC). The RISC binds the target mRNA and silences 
gene expression by cleaving it (Figure II.3). Since DICER can cleave hairpin 
RNAs, DNA vectors that contain such RNA substrates are commonly used. 
Another possibility is to introduce post-DICER cleavage products (siRNAs) to 
initiate RNAi. In the present work both systems are used. DNA vectors were 
applied for silencing Smac and short interfering (si) RNA for caspase-2, AIF and 
RAIDD.  
 
9.1 siRNAs TARGETING CASPASE-2, AIF AND RAIDD 
 
Sense and antisense siRNA oligonucleotides corresponding to nucleotides 94-114 
of caspase-2 (5´-aaacagctgttgttgagcgaa-3´) (72), nucleotides 6-27 of RAIDD (5`-
ggccagagacaaacaagtactc-3`) (56), AIF nucleotides ggaaatatgggaaagatccdTdT, 
(73) and oligonucleotides corresponding to a nonsense sequence were purchased 
from Biomers.net GmbH (Ulm, Germany). The single stranded siRNA 
oligonucleotides were dissolved to 100 µM stock solutions in RNase free water. 
They were annealed to create the 20 µM double-stranded siRNAs as follows: 15 µl 
of sense and 15 µl of antisense siRNA were combined with 30 µl RNase free H2O 
and 15 µl annealing buffer (Ambion). This solution was incubated at 90°C for 
1 minute and was left to cool down until temperature reached 37°C. Afterwards the 
double stranded siRNA was incubated for further 5 minutes at room temperature 
and stored at -20°C. 
 
9.2 SMAC siRNA 
 
The plasmids bearing siRNAs against Smac, a nonsense sequence and the vector 
alone were kindly provided by Dr. S. Fulda (University Hospital Ulm, Germany). 
Two siRNAs against Smac were used:  
pSUPER.retro129 
(5´-gatccccgaagcggtgtttctcagaattcaagagattctgagaaacaccgcttctttttggaaa-3´) 
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and pSUPER.retro1188  
(5´-gatcccccctgtccagtttgtacgatttcaagagaatcgtacaaactggacaggtttttggaaa-3´). 
For propagation, the plasmids were transformed into DH5α and a glycerol stock 
was raised (see chapter II9.2.1). 
 
9.2.1 TRANSFORMATION OF DH5α 
 
E.coli strain DH5α was transformed as follows: 1 µg of each plasmid was 
incubated with 100 µl of bacteria on ice for 30 min, followed by 30 seconds at 
42°C. Afterwards bacteria were placed back on ice for 1-2 min. 900 µl of room 
temperature lysogeny broth (LB) medium (Gibco/Invitrogen, Karlsruhe, Germany) 
were added to each tube and bacteria were incubated in a water bath at 37°C for 
90 min. 50 µl of bacteria suspension were spread onto ampicillin (Calbiochem, 
Schwalbach, Germany)-agar plates. Plates were incubated at 37°C overnight. 
 
 
LB agar  
Lennox L Broth Base 20 g 
Agar   15 g 
Ampicillin (100 mg/ml) 1 ml 
H2O ad 1,000 ml 
LB medium 
Lennox L Broth Base 20 g 
Ampicillin (100 mg/ml)  1 ml 
H2O ad 1,000 ml
Ampicillin was added to LB medium freshly before use. 
 
9.2.2 PLASMID AMPLIFICATION AND PURIFICATION 
 
Colonies were picked from the agar plates and inoculated in 2-3 ml of LB medium 
containing ampicillin. Bacteria were grown in a thermoshaker (Thermoshake 
THO 500, Gerhardt, Königswinter, Germany) over night at 37°C. Afterwards, a part 
of the bacteria culture was used to isolate the plasmids with a QIAprep® Miniprep 
kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instruction and 
dissolved in nuclease-free H2O. Presence of plasmids was confirmed by running 
probes in 1 % agarose gels. Subsequent, bacteria cultures were expanded and 
plasmid isolation was done by a QIAprep® Maxiprep kit. Received plasmids were 
dissolved in nuclease-free H2O and stored at -20°C. 
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To preserve the bacteria cultures glycerol stocks were prepared by mixing 775 µl 
of an overnight bacteria culture with 225 µl of 80% glycerol and frozen at -80°C. 
 
9.3 TRANSFECTION OF JURKAT CELLS 
 
Jurkat cells were transfected by electroporation with the Nucleofector™ II device 
(Amaxa, Cologne, Germany) according to the manufacturer’s protocol. 4 x 106 
Jurkat T cells in exponential growing phase were transfected with 2 µg of 
pSUPER.retro129 and 2 µg of pSUPER.retro1188 in a 1:1 mixture of the siRNA 
constructs. Antibiotic selection with 2 µg/ml puromycin was started the day after 
transfection. After another 24 h antibiotic was removed. Cells were seeded and 
stimulated on day 4 after nucleofection. Efficiency of RNA interference was 
checked by Western Blot analysis using antibodies against Smac/DIABLO. Cells 
transfected with siRNAs targeting AIF, caspase-2 and RAIDD were used 24 hours 
after transfection. 
 
 
10 STATISTICS 
All experiments were performed at least three times. Results are expressed as 
mean value ± SEM. Statistical analysis was performed with GraphPad PrismTM 
version 3.03 using one-way ANOVA with Bonferroni or Dunnett multiple 
comparison post-test or unpaired two-tailed Student´s T test. P values < 0.05 were 
considered significant. 
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III RESULTS 
 
1 CYTOTOXICITY OF CEPHALOSTATIN 2, 10 AND 12 
1.1 CEPHALOSTATIN 2 IS THE MOST ACTIVE OF THE 
CEPHALOSTATINS 
 
In order to investigate the cytotoxic effects of cephalostatin (CPH) 2, 10, and 12 
the MTT assay was used. Jurkat T cells were incubated with increasing 
concentrations of the different CPHs for 24 hours. Dose response curves (Figure 
III.1) were created and IC50 values were calculated. The IC50 value for 
cephalostatin 2 is 1 nM, for cephalostatin 10 is 9.7 nM and the IC50 value for 
cephalostatin 12 is 560 nM, clearly pointing to the highest cytotoxic activity for 
cephalostatin 2. 
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Figure III.1 Cephalostatin 2 is the most active among the tested cephalostatins 
Jurkat T cells were left either untreated (CO) or stimulated with increasing concentrations of 
CPH 2, 10 or 12 for 24 hours. Impairment of cell viability was analyzed by MTT assay as described 
in “Materials and Methods”. Represented are the mean ± SEM of at least three independent 
experiments. 
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1.2 APOPTOSIS INDUCTION BY CEPHALOSTATIN 2, 10 AND 12 
 
In order to examine whether the observed cytotoxicity is due to programmed cell 
death, a classical feature of apoptosis, the DNA-fragmentation, was measured by 
staining with propidium iodide according to the Nicoletti method. As expected from 
the IC50 values cephalostatin 2 was the strongest inducer of apoptosis in Jurkat T 
cells. Apoptosis is already significantly induced at a concentration of 5 nM (see 
Figure III.2) whereas a significant onset of DNA-fragmentation for CPH 10 starts at 
500 nM and for CPH 12 at 1 µM.  
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Figure III.2 Apoptosis induced by cephalostatin 2, 10 and 12 is dose dependent 
Cells were left untreated (CO) or treated with cephalostatin 2, 10 or 12 (CPH 2, CPH 10, and 
CPH 12) in increasing concentrations for 24 hours. Apoptotic cells were quantified by flow 
cytometry as described in “Materials and Methods”. All experiments were carried out three times. 
Bars, the mean ± SE of three independent experiments performed in triplicate. (*, P < 0.05; **, P < 
0.01 ANOVA/Dunnett). 
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Since cephalostatin 2 is the most potent inductor of apoptosis, it was used for all 
further experiments. For all investigations in Jurkat T cells 50 nM CPH 2 was 
applied, which induces about 40% DNA-fragmentation after 24 h of treatment 
(Figure III.2). Furthermore, the response of Jurkat cells to CPH 2 preceded 
dependent on time (Figure III.3), reaching a significant level after 24 h of 
treatment. 
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Figure III.3 Cephalostatin 2 induced apoptosis is dependent on time 
Cells were left untreated (CO) or treated with 50 nM cephalostatin 2 for the indicated times. 
Apoptotic cells were quantified by flow cytometry as described in “Materials and Methods”. All 
experiments were carried out three times. Bars, the mean ± SE of three independent experiments 
performed in triplicate. (**, P < 0.01 ANOVA/Dunnett).  
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2 CEPHALOSTATIN 2 INDUCED APOPTOSIS IS NOT 
RESTRICTED TO JURKAT T CELLS 
2.1 APOPTOSIS INDUCTION IN HELA CELLS 
 
To investigate whether apoptosis mediated by cephalostatin 2 is restricted to 
Jurkat T cells the impact of the substance on different carcinoma cell lines was 
determined. The first cell line, established in 1951 from human tissue, is the cervix 
carcinoma cell line HeLa, which is now one of the most common cell lines 
worldwide. HeLa cells were treated with cephalostatin for different time periods 
and DNA-fragmentation was measured by the Nicoletti method. Figure III.4 shows 
that cephalostatin induces time dependently cell death, reaching significance after 
treatment for 40 hours. 
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Figure III.4 Cephalostatin induces apoptosis in HeLa cells 
HeLa cells were left untreated (CO) or treated with 50 nM cephalostatin 2 for the indicated times. 
Apoptotic cells were quantified by flow cytometry as described in “Materials and Methods”. All 
experiments were carried out two times. Bars, the mean ± SE of two independent experiments 
performed in triplicate. (**, P < 0.01 ANOVA/Dunnett). 
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2.2 APOPTOSIS INDUCTION IN MCF-7 CELLS 
Next, the breast adenocarcinoma cell line MCF-7, which is deficient for caspase-3 
due to a deletion mutation (74), and the caspase-3 reconstituted cell line were 
tested for apoptosis induction by cephalostatin. As described in I.4, apoptotic cells 
detach and undergo morphological changes like cell shrinkage and the formation 
of apoptotic bodies.  
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Figure III.5 Morphological alterations in cephalostatin-treated MCF-7 cells 
A) Light microscopic pictures of MCF-7 ± caspase-3 cells. MCF-7 (upper panel) and caspase-3 
reconstituted (lower panel) cells were left untreated (CO) or treated with 1 µM cephalostatin 2 
(CPH). After 24 h treatment pictures were taken. B) Fluorescence microscopy pictures of MCF-7 ± 
caspase-3 cells. MCF-7 (upper panel) and caspase-3 reconstituted (lower panel) cells were left 
untreated (CO) or treated with 1 µM cephalostatin 2 (CPH) for 24 h. Nuclei were stained with 
Hoechst 33342 and analyzed by fluorescence microscopy. 
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Treatment with cephalostatin 2 induces the detachment of MCF-7 cells with or 
without caspase-3 and initiates strong cell shrinkage after 24 hours (Figure III.5 A).  
Besides changes in size and shape of the whole cell, the nucleus of an apoptotic 
cell is subject of numerous biochemical processes as well. EndoG and other 
enzymes condense the chromatin and finally the DNA is fragmented by 
endonucleases like CAD (caspase-activated DNase). Upon staining 24 h 
cephalostatin 2 treated cells with the vital dye Hoechst 33342 condensation of the 
DNA can clearly be observed (Figure III.5). Untreated cells show faint blue 
staining, whereas treated cells show intensive blue colour indicating chromatin 
condensation. If stimulation with cephalostatin is extended from 24 to 48 h also 
DNA-fragmentation can be measured by PI-staining (Figure III.6). Interestingly, 
cephalostatin mediated cell death is not amplified by reconstitution of caspase-3. 
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Figure III.6 Cephalostatin induces apoptosis in MCF-7 ± caspase-3 cells 
Cells were left untreated (CO) or treated with 1 µM cephalostatin 2 (CPH) for 48 h. Apoptotic cells 
were quantified by flow cytometry as described in “Materials and Methods”. All experiments were 
carried out two times. Bars, the mean ± SE of two independent experiments performed in 
triplicates. (P < 0.05 ANOVA/Dunnett, n.s. not significant). 
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2.3 CELL DEATH INDUCTION IN SK-MEL-5 CELLS 
2.3.1 APOPTOSIS INDUCTION 
 
Metastatic melanoma is a very aggressive form of skin cancer, which is resistant 
to most forms of therapy, including systemic therapy and immunotherapy. The 
combination of chemotherapy and e.g. interleukin-2 has failed in clinical trials, 
implying resistance mechanisms in melanoma, which are highly complex (61). For 
this reason the melanoma cell line SK-Mel-5 was employed to test the activity of 
cephalostatin. As shown in Figure III.7 cephalostatin 2 induces dose dependent 
DNA-fragmentation after 48 h of treatment, becoming significant at a concentration 
of 100 nM. For further experiments cephalostatin was used in a concentration of 
1 µM. Taxol also induces apoptosis and was used as positive control. 
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Figure III.7 Cephalostatin induces concentration dependent apoptosis in SK-Mel-5 cells 
Cells were left untreated (CO), treated with increasing concentrations of cephalostatin 2 (CPH) or 
with 50 nM taxol (TAX) for 48 h. Apoptotic cells were quantified by flow cytometry as described in 
“Materials and Methods”. All experiments were carried out at least two times. Bars, the mean ± SE 
of at least two independent experiments performed in triplicates. (**, P < 0.01 ANOVA/Dunnett). 
 
As for Jurkat and HeLa cells cephalostatin 2 induced apoptosis proceeds with time 
as shown by MTT (Figure III.8 upper panel) and Nicoletti test (Figure III.8 lower 
panel), but cephalostatin has to be applied for a longer time and in a 20-fold higher 
concentration to get comparable apoptosis levels than in Jurkat of HeLa cells. This 
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sustains the fact, that melanoma belong to the more chemoresistant tumors. Since 
cell viability of SK-Mel-5 is still about 50% after 3 days of treatment a long term 
assay was performed in order to investigate if the remaining viable cells retain 
their ability to grow.  
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Figure III.8 Cephalostatin induces time dependent cell death in SK-Mel-5 cells 
Upper panel: SK-Mel-5 cells were left either untreated (CO) or stimulated with 1 µM cephalostatin 2 
for 16 up to 72 hours. Impairment of cell viability was analyzed by MTT assay as described in 
“Materials and Methods”. Represented are the mean ± SEM of three independent experiments (**, 
P < 0.01 ANOVA/Dunnett). Lower panel: SK-Mel-5 cells were left either untreated (CO) or 
stimulated with 1 µM cephalostatin 2 for 48 up to 96 hours. DNA-fragmentation was analyzed by 
the Nicoletti method as described in “Materials and Methods”. Represented are the mean ± SEM of 
three independent experiments (**, P < 0.01 ANOVA/Dunnett). 
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2.3.2 CEPHALOSTATIN STRONGLY INHIBITS CLONAL TUMOR CELL 
GROWTH 
 
As long term assay the clonogenic or colony formation assay was performed. It is 
an in vitro cell survival assay to determine the effectiveness of cytotoxic agents. It 
essentially tests every cell in the population for its ability to undergo unlimited 
division. The difference to short term tests like the measurement of DNA-
fragmentation is that cells are not evaluated after e. g. a short period of 24 h but 
instead are left to grow for one week. Thus it can be ascertained whether the 
percentage of cells that do not show DNA-fragmentation in the Nicoletti assay or 
are still viable in MTT assay die later or are able to grow and form new colonies, a 
clear sign of chemoresistance. Beyond that, cells are treated for just 2 hours with 
cephalostatin, a mode which is closer related to in vivo conditions in 
chemotherapy.  
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Figure III.9 Cephalostatin strongly inhibits clonogenic tumor growth 
Left panel: SK-Mel-5 cells were seeded as described in “Materials and Methods” and left untreated 
(CO) or stimulated with 50 nM cephalostatin-2 (CPH) or 50 nM taxol (TAX) for 2 hours. Sub-
sequent, cells were detached, washed with PBS and seeded again in a concentration of 10,000 
cells/well. Cells were left to grow for one week and stained with crystal violet. Intracellular crystal 
violet was solved and absorption at 550 nM was measured. Absorption of untreated cells was set 
100% viability. Represented are the mean ± SEM of three independent experiments (**, P < 0.01; 
***, ### P < 0.001 unpaired two-tailed t test). Right panel: Before solving intracellular crystal violet 
pictures were taken. One representative picture out of three independent experiments performed in 
triplicates is shown. 
III RESULTS 
 53   
Normally, colonies can be counted after staining with crystal violet, but since SK-
Mel-5 cells do not form colonies but grow as a loosely spread network, pictures 
were taken and after solving the dye, absorption was measured and the 
percentage of viable cells was calculated by setting untreated cells 100% viable. 
Cephalostatin-treatment results in strong inhibition of clonogenic tumor growth as 
shown in Figure III.9. Most importantly, taxol which is also able to induce apoptosis 
measured by DNA-fragmentation (see Figure III.7) to a comparable extent has an 
explicit lower capacity of inhibiting the growth of SK-Mel-5 melanoma cells than 
cephalostatin. This clearly points to the potential of cephalostatin to fight 
chemoresistance. 
3 CEPHALOSTATIN INDUCES CASPASE-DEPENDENT 
AND -INDEPENDENT CELL DEATH 
3.1 CASPASE-DEPENDENT APOPTOSIS 
Caspases are the major executioners of classical apoptotic morphology induced 
by varying stimuli. But there is growing evidence that apoptotic cell death can also 
be mediated by other factors like cathepsins, calpains or AIF (41, 75, 76). 
Cephalostatin is known to mediate apoptosis via caspases in Jurkat T cells (15). 
Figure III.10 A shows that apoptosis in Jurkat cells can be inhibited by use of the 
broad range caspase inhibitor zVADfmk (25 µM).
In order to prove that this is not a cell type specific phenomenon additional cell 
lines were investigated. HeLa cells were preincubated for 1 h with the 
PANcaspase inhibitor zVADfmk (25 µM) and apoptosis was measured by FACS 
analysis. As expected, Figure III.10 B show that caspase inhibition prevents 
cephalostatin-2 induced DNA-fragmentation in HeLa cells, indicating that the 
signaling pathway relies on caspases in these cells. The same observation is 
made for etoposide, a classical caspases-dependent inducer of apoptosis. 
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Figure III.10 Caspase-dependent apoptosis in Jurkat and HeLa cells 
A) Jurkat cells were left untreated (CO) or treated with 50 nM cephalostatin 2 or 2 µM etoposide 
(ETO) for 24 h. Cells were preincubated with 25 µM PANcaspase inhibitor zVADfmk for 1 h. 
Apoptotic cells were quantified by flow cytometry as described in “Materials and Methods”. All 
experiments were carried out two times. Bars, the mean ± SE of two independent experiments 
performed in triplicate. (**, P < 0.01; ***, P < 0.001 unpaired two-tailed t test). B) HeLa cells were 
left untreated (CO) or treated with 50 nM cephalostatin 2 or 10 µM etoposide (ETO) for 40 h. Cells 
were preincubated with 25 µM PANcaspase inhibitor zVADfmk for 1 h. Apoptotic cells were 
quantified by flow cytometry as described in “Materials and Methods”. All experiments were carried 
out three times. Bars, the mean ± SE of three independent experiments performed in triplicate 
(*, P < 0.05; ***, P < 0.001 unpaired two-tailed t test).  
 
 
 
 
 
III RESULTS 
 
  55   
3.2 CASPASE-INDEPENDENT APOPTOSIS 
 
As another model the ovarian cancer cell line SK-OV-3 was employed. 
Cephalostatin is able to induce apoptosis in these cells, but surprisingly a different 
result concerning caspase dependence is obtained (Figure III.11).  
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Figure III.11 Caspase-independent cell death in SK-OV-3 cells 
SK-OV-3 cells were left untreated (CO) or treated with 1 µM cephalostatin 2 (CPH) or 50 µM 
etoposide (ETO) for 48 h. Cells were preincubated with 25 µM PANcaspase inhibitor zVADfmk for 
1 h. Apoptotic cells were quantified by flow cytometry as described in “Materials and Methods”. All 
experiments were carried out two times. Bars, the mean ± SE of two independent experiments 
performed in triplicate. (n.s. not significant; * P < 0.05 unpaired two-tailed t test). 
 
Although a slight decrease in cephalostatin-caused DNA-fragmentation is 
observed, this inhibition by zVADfmk is – contrary to etoposide – not significant. 
This is evidence to suggest, that – dependent on cell type – there exists a 
caspase-independent besides the caspase-dependent mechanism by which 
cephalostatin induces cell death. 
This observation was further confirmed by caspase-inhibitory experiments in the 
SK-Mel-5 cell line. The application of zVADfmk could not block apoptosis induction 
as well. To exclude that this caspase inhibitor is not able to prevent caspase 
activity another cell permeable, irreversible broad-spectrum caspase inhibitor 
QVD-OPh (N-(2-Quinolyl)valyl-aspartyl-(2,6-difluorophenoxy)methyl ketone) was 
used.  
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Figure III.12 Cephalostatin induced cell death in SK-Mel-5 cells is caspase-independent 
SK-Mel-5 cells were left untreated (CO) or treated with 1 µM cephalostatin 2 (CPH) for 48 h. Cells 
were preincubated with 25 µM PANcaspase inhibitor zVADfmk (left panel) or 500 nM QVD-OPh 
(right panel) for 1 h. Apoptotic cells were quantified by flow cytometry as described in “Materials 
and Methods”. All experiments were carried out three times. Bars, the mean ± SE of three 
independent experiments performed in triplicate. (n.s. not significant; * P < 0.05 unpaired two-tailed 
t test). 
 
Again, no inhibition of cephalostatin 2 induced cell death could be achieved, 
confirming the concomitance of caspase-dependent and independent pathways for 
cephalostatin contingent on the used cell type. 
 
 
4 CELL DEATH INDUCTION IN SK-MEL-5  
4.1 STAT3 IS DEGRADED UPON CEPHALOSTATIN TREATMENT 
 
STAT3 (Signal transducer and activator of transcription 3) is an important 
molecule mediating tumor-cell proliferation and survival, tumor angiogenesis and 
invasion. Activation of STAT3 involves phosphorylation on tyrosine 705 
(dimerization, nuclear translocation and DNA binding) and serine 727 
(transcriptional activity). In normal cells activation of STAT3 is rapid and transient, 
whereas it is proved constitutively active in a growing number of human cancer 
cell lines. Thus STAT3 has emerged as an important target for cancer therapy 
(37). As shown by clonal survival assay proliferation of SK-Mel-5 cells is strongly 
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inhibited upon cephalostatin treatment. Therefore we were interested if STAT3 as 
a central tumor survival signaling molecule is affected by cephalostatin. SK-Mel-5 
cells were treated with 1 µM cephalostatin 2 for 24 up to 48 h. As shown in Figure 
III.13 cephalostatin promotes STAT3 inhibition not only by preventing the 
phosphorylation on tyrosine 705 but also by degrading the serine 727 
phosphorylated form and the total protein.  
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Figure III.13 Cephalostatin promotes STAT3 degradation 
SK-Mel-5 cells were either left untreated (CO harvested together with the 24 and 32 h treated 
samples, C0/48 harvested together with the 40 and 48 h treated samples) or treated with 
cephalostatin 2 (CPH; 1 µM) for the indicated times. Total STAT3 level and phosphorylation of 
STAT3 on Tyr 705 and Ser 727 was analyzed by Western blot. Equal protein loading was 
controlled by staining membranes with Ponceau S (a representative section of the stained 
membrane is shown). All experiments were carried out two times. 
 
 
4.2 CEPHALOSTATIN INDUCES CELL CYCLE ARREST AT G1 
PHASE 
 
The oncogenic transcription factor STAT3 upregulates many tumorigenic genes, of 
which Bcl-xL was discovered first. Since then many other proteins that are crucially 
involved in tumor cell proliferation and survival have been found to be under the 
control of STAT3, including Mcl-1, survivin and cyclin D1 (37).  
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Figure III.14 Cephalostatin induces G1-phase arrest in SK-Mel-5 cells 
Upper panel: SK-Mel-5 cells were either left untreated (CO) or treated with cephalostatin 2 (CPH; 
1 µM) for 24 h. Cells were harvested and stained with PI as for the Nicoletti method described in 
“Materials and Methods”. Cell cycle distribution was quantified by flow cytometry. A representative 
histogram out of three independent experiments is shown. Lower panel: SK-Mel-5 cells were either 
left untreated (CO) or treated with cephalostatin 2 (CPH; 1 µM) for 24 h. Cells were harvested and 
stained with PI as for the Nicoletti method described in “Materials and Methods” Cell cycle 
distribution was quantified by flow cytometry. All experiments were carried out three times. Bars, 
the mean ± SE of three independent experiments performed in triplicates. (*, P < 0.05 unpaired 
two-tailed t test) 
 
Since cyclin D1 promotes cell cycle transition from G1 to S-Phase we investigated 
the influence of cephalostatin on cell cycle distribution of SK-Mel-5 cells.  
Indeed, the percentage of cells in G1 phase increases significantly whereas fewer 
cells are found in S and G2/M Phase upon cephalostatin treatment for 24 hours 
(Figure III.14). 
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4.3 SURVIVIN IS DEGRADED UPON CEPHALOSTATIN 2 
TREATMENT 
 
Survivin, another STAT3 regulated protein, which belongs to the IAP family, 
inhibits apoptosis and thus we were interested if survivin is influenced by 
cephalostatin. As shown in Figure III.15 survivin is completely degraded upon 
cephalostatin treatment.  
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Figure III.15 Cephalostatin promotes survivin downregulation 
SK-Mel-5 cells were either left untreated (CO harvested together with the 24 and 32 h treated 
samples, C0/48 harvested together with the 40 and 48 h treated samples) or treated with 
cephalostatin 2 (CPH; 1 µM) for the indicated times. Survivin level was analyzed by Western blot. 
Equal protein loading was controlled by staining membranes with Ponceau S (a representative 
section of the stained membrane is shown). All experiments were carried out three times. 
 
4.4 AIF IS NOT RESPONSIBLE FOR APOPTOSIS INDUCTION IN 
SK-MEL-5 CELLS 
 
As a consequence of survivin downregulation the release of mitochondrial proteins 
and caspase-dependent as well as caspase-independent apoptosis is observed 
(62, 63). AIF is one of the factors known to induce caspase-independent DNA-
fragmentation (77). Since cephalostatin-induced apoptosis is not dependent on 
caspases in SK-Mel-5 cells, we were interested if AIF mediates cell death in this 
case. Therefore, we applied siRNA technique in order to investigate the effect of 
AIF on cephalostatin mediated apoptosis. As shown in Figure III.16 (lower panel) 
cells were effectively transfected with siRNA targeting AIF. As control a nonsense 
siRNA was used. Cells were treated with cephalostatin 2 for 48 h and DNA-
fragmentation was determined by FACS analysis. No difference in apoptosis 
induction could be detected between cells transfected with AIF siRNA and 
nonsense siRNA upon cephalostatin treatment. In order to avoid that the lack of 
AIF induces caspase-dependent apoptosis as a compensatory mechanism, we 
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used the broad-spectrum caspase inhibitor Q-VD-OPh. But this also could not 
prevent cell death, suggesting a caspase as well as AIF independent mechanism 
of apoptosis for cephalostatin in the SK-Mel-5 cell line. 
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Figure III.16 AIF is not responsible for cephalostatin induced apoptosis in SK-Mel-5 cells 
Upper panel: SK-Mel-5 cells were transfected with siRNA targeting AIF or a scramble siRNA as 
described in “Materials and Methods”. Cells were preincubated with 500 nM Q-VD-OPh (right 
panel) for 1 h. Cells were left untreated (CO) or treated with cephalostatin 2 (CPH; 1 µM) for the 
indicated times. Apoptotic cells were quantified by flow cytometry as described in “Materials and 
Methods”. Downregulation of AIF was verified by Western Blot. Equal protein loading was 
controlled by staining membranes with Ponceau S (a representative section of the stained 
membrane is shown). All experiments were carried out two times. Bars, the mean ± SE of two 
independent experiments performed in triplicates (n.s. not significant P < 0.05; unpaired two-tailed t 
test). 
 
III RESULTS 
 
  61   
5 CEPHALOSTATIN INDUCES PREFERENTIAL SMAC 
RELEASE 
5.1 SMAC BUT NOT CYTOCHROME C IS PREDOMINATELY 
RELEASED IN VARIOUS TUMOR CELLS UPON 
CEPHALOSTATIN TREATMENT. 
 
A characteristic event in cephalostatin-induced apoptosis is the selective 
mitochondrial release of Smac but not cytochrome c in Jurkat leukemia T cells 
(15). Figure III.17 shows that upon cephalostatin (CPH)-treatment only Smac is 
released into cytosol, whereas staurosporine (ST) strongly induces the release of 
Smac and cytochrome c. 
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Figure III.17 Smac is selectively released in Jurkat T cells 
Jurkat T cells were either left untreated (CO) or treated with cephalostatin 2 (CPH; 50 nM) or 
staurosporine (ST; 1 µM, 8 h) for the indicated times. Smac and cytochrome c release was 
analyzed by Western blot. Equal protein loading was controlled by staining membranes with 
Ponceau S (a representative section of the stained membrane is shown). All experiments were 
carried out three times. 
 
To further confirm that this unusual finding is not a cell type-specific phenomenon, 
but a characteristic event for cephalostatin-induced apoptosis, we investigated the 
release of Smac and cytochrome c in two further cell lines, SK-Mel-5 and MCF-7 
cells. As seen in Figure III.18 A and Figure III.18 B (right panel), Smac - in contrast 
to cytochrome c - is rapidly and markedly released from mitochondria upon 
cephalostatin treatment in SK-Mel-5 and MCF-7 cells, whereas staurosporine and 
etoposide induce the translocation of both proteins into cytosol. These results 
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were further supported by confocal microscopy studies (Figure III.18 B left panel) 
using MCF-7 cells either expressing cytochrome c-GFP or Smac-YFP. Untreated 
control cells show the co-localization of cytochrome c-GFP and Smac-YFP with a 
mitochondrial dye, proofing the mitochondrial localization of the fusion proteins.  
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Figure III.18 Smac is selectively released upon cephalostatin treatment regardless of cell 
type 
A) SK-Mel-5 cells were either left untreated (CO) or treated with cephalostatin 2 (CPH; 1 µM) or 
etoposide (ETO; 10 µM, 24 h) for the indicated times. Smac and cytochrome c release was 
analyzed by Western blot. Equal protein loading was controlled by staining membranes with 
Ponceau S (a representative section of the stained membrane is shown). B) MCF-7 cells stably 
expressing either cytochrome c-GFP or Smac-YFP were left untreated (CO) or treated with 
cephalostatin 2 (CPH; 50 nM) or staurosporine (ST; 1 µM) for the indicated times. Smac and 
cytochrome c release were analyzed by confocal microscopy as well as Western blot as described 
in “Materials and Methods”. Mitochondria are shown in red; merge of mitochondria with 
cytochrome c-GFP or Smac-YFP is shown yellow. Smac and cytochrome c released into cytosol is 
displayed green. 
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After stimulation with cephalostatin Smac-YFP is found in cytosol whereas 
cytochrome c-GFP is still mitochondria-localized. In contrast, staurosporine 
induces the release of both proteins. 
 
 
6 MECHANISM OF CEPHALOSTATIN-INDUCED SMAC 
RELEASE 
6.1 SMAC RELEASE IS NOT MEDIATED BY JNK OR CASPASE-2 
 
Smac can be released from mitochondria in several ways. A few reports (78, 79) 
show that JNK is involved in the release of Smac from mitochondria. Since 
cephalostatin activates JNK (16), we investigated the impact of JNK and its 
upstream regulatory kinase ASK1 on cephalostatin-induced Smac release. As 
shown in Figure III.19, neither the inhibition of JNK by the inhibitor SP600125 nor 
the use of Jurkat cells that express an inactive form of ASK1, an upstream 
regulatory kinase of JNK, could prevent cephalostatin-induced Smac release. 
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Figure III.19 Cephalostatin induced Smac release is not dependent on JNK 
Left panel: ASK1-DN Jurkat cells were left untreated (CO) or treated with cephalostatin 2 (CPH; 
50 nM) for the indicated times and Smac release was analyzed by Western blot. Right panel: 
Jurkat cells were left untreated (CO) or treated with cephalostatin 2 (CPH; 50 nM) for the indicated 
times. 30 min prior to stimulation cells were incubated with 10 µM JNK inhibitor SP600125. Smac 
release was analyzed by Western blot. Equal protein loading was controlled by staining 
membranes with Ponceau S (a representative section of the stained membrane is shown). All 
experiments were carried out three times. 
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As previously shown by our group, the PANcaspase inhibitor zVADfmk does not 
inhibit cephalostatin-induced Smac release (15). Due to the fact that caspase-2 is 
supposed to be insensitive against zVADfmk (80) and can directly influence 
mitochondria (81, 82, 83), the specific inhibitor of caspase-2 benzyloxycarbonyl-
Val-Asp-Val-Ala-Asp-fluoromethylketone (zVDVADfmk) was used, but again no 
inhibition of Smac release could be observed (Figure III.20).  
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Figure III.20 Cephalostatin induced Smac release is not dependent on caspase-2 
Jurkat cells were left untreated (CO) or treated with cephalostatin 2 (CPH; 50 nM) for the indicated 
times. Prior to stimulation cells were incubated for 1 hour with 20 µM zVDVADfmk, a specific 
caspase-2 inhibitor. Smac release was analyzed by Western blot. Equal protein loading was 
controlled by staining membranes with Ponceau S (a representative section of the stained 
membrane is shown). All experiments were carried out three times. 
 
6.2 BAK DEFICIENCY DELAYS BUT CAN NOT PREVENT SMAC 
RELEASE 
 
The onset of Smac release and induction of apoptosis induced by cephalostatin is 
known to be inhibited by overexpression of the antiapoptotic protein Bcl-xL (15). 
Since Jurkat cells do not express Bax (84) we used Jurkat cells additionally 
deficient for Bak to investigate the impact of these proapoptotic proteins on Smac 
release. As shown in Figure III.21A, Bak deficiency delayed, but did not prevent 
the onset of Smac release in cephalostatin-treated Jurkat cells (experiment 
performed by Dr. Nancy López-Antón). The cells are resistant to apoptotic stimuli 
like staurosporine and taxol, but cephalostatin-induced cell death (Figure III.21B) 
was not influenced. Staurosporine and taxol use the intrinsic pathway, 
characterized by cytochrome c release, further pointing to a cytochrome c 
independent signaling pathway for cephalostatin, in which Smac could play an 
important role.  
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Figure III.21 Bak deficiency can not prevent Smac release and apoptosis induced by 
cephalostatin 
A) Bak reconstituted (Bak+/+) and Bak deficient (Bak-/-) Jurkat cells were left untreated (CO) or 
treated with cephalostatin 2 (CPH; 50 nM) for the indicated times. Smac release was analyzed by 
Western blot. Equal protein loading was controlled by staining membranes with Ponceau S (a 
representative section of the stained membrane is shown). All experiments were carried out three 
times. B) Bak-reconstituted (Bak+/+) and Bak-deficient (Bak-/-) Jurkat cells were left untreated 
(CO) or treated with 50 nM cephalostatin 2 (CPH), 250 nM staurosporine (STA) or 1 µM taxol 
(TAX) for 24 hours. Apoptotic cells were quantified by flow cytometry as described in “Materials and 
Methods”. Protein extracts from Bak+/+ and Bak-/- cells were prepared and Bak levels analyzed by 
Western blot. β-Actin was used as loading control (right panel). 
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6.3 SMAC RELEASE IS PARTIALLY DEPENDENT ON CALPAIN 
 
The Ca2+-dependent calpain family of cysteine proteases is known to mediate 
apoptosis upon several conditions, amongst others by cleaving Bcl-2 family 
proteins and inducing release of mitochondrial factors. Calpain is activated upon 
Ca2+ binding and further autolytic processing to its 76 kDa subunit (85, 86). In fact, 
cephalostatin leads to calpain activation already after one hour of treatment 
(Figure III.22, upper panel; experiment was performed by Dr. Irina Müller). Due to 
this fast activation we investigated a possible influence of calpain on the selective 
Smac release by employing the inhibitor calpastatin, which was coupled to 
penetratin. Interestingly, cephalostatin-induced Smac release into cytosol was 
diminished by calpain inhibition (Figure III.22, lower panel). 
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Figure III.22 Cephalostatin induced Smac release is partially mediated by calpain 
Upper panel: Jurkat cells were left untreated (CO) or treated with cephalostatin for the indicated 
times. The calcium ionophore A23187 (A; 1 µM 16 h) was used as positive control. Calpain 
activation was analyzed by Western blot. Lower panel: Jurkat cells were left untreated (CO) or 
treated with cephalostatin (CPH, 50 nM) for 2 hours. 1 hour prior to stimulation cells were 
incubated with 500 nM calpastatin-penetratin. Smac release was analyzed by Western blot. Equal 
protein loading was controlled by staining membranes with Ponceau S (a representative section of 
the stained membrane is shown). All experiments were carried out three times. 
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7 IMPACT OF SMAC ON CEPHALOSTATIN-INDUCED 
APOPTOSIS 
7.1  XIAP OVEREXPRESSION CAN NOT PREVENT APOPTOSIS 
 
Inhibitor of apoptosis proteins (IAPs) are shown to be expressed to a higher extent in 
cancer than in normal tissue and are connected to chemoresistance. Smac/DIABLO binds 
to various IAPs thus neutralizing their inhibitory effect on caspases. The BIR3 domain of 
X-linked IAP (XIAP), the most potent member of the IAP family, is recognized by mature 
Smac/DIABLO. Thus, Smac is able to compete with caspase-9 for binding to the BIR3 
domain of IAPs and thereby favors its activation. Smac/DIABLO also binds to the BIR2 
motif of XIAP, thereby counteracting the XIAP-dependent inhibition of caspase-3 and -7 
(34). If Smac is functional and important in cephalostatin induced cell death it thus should 
counteract XIAP overexpression. Therefore, apoptosis was measured in XIAP 
overexpressing in comparison to wildtype Jurkat cells. Figure III.23 strikingly shows that 
cephalostatin induced cell death is not influenced by XIAP overexpression, whereas 
etoposide mediated cell death is almost completely inhibited.  
0
20
40
60
80
100
XIAP (57 kDa)
S XIAP
S-Jurkat
XIAP
CO 50nM CPH 2µM ETO
%
 a
po
pt
ot
ic
ce
lls
***
n.s.
Ponceau S
 
 
Figure III.23 XIAP overexpression does not prevent cephalostatin-induced cell death 
XIAP overexpressing (XIAP) and wildtype Jurkat (S-Jurkat) cells were left untreated (CO) or treated 
with 50 nM cephalostatin 2 (CPH) or 2 µM etoposide (ETO) for 24 hours. Apoptotic cells were 
quantified by flow cytometry as described in “Materials and Methods”. Protein extracts from XIAP 
and S-Jurkat cells were prepared and XIAP levels analyzed by Western Blot. Equal protein loading 
was controlled by staining membranes with Ponceau S (a representative section of the stained 
membrane is shown). All experiments were carried out three times (n.s. not significant; ***, 
P < 0.001 (unpaired two-tailed t test). 
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7.2 SMAC SILENCING INHIBITS CEPHALOSTATIN-INDUCED 
APOPTOSIS 
 
Due to the unique characteristic of cephalostatin to induce a selective Smac 
release, we investigated the role of Smac in cephalostatin-induced cell death by 
silencing the Smac gene via siRNA. As shown in Figure III.24, silencing of Smac 
significantly inhibited cephalostatin-induced apoptosis.  
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Figure III.24 Smac siRNA inhibits cephalostatin-induced apoptosis 
Jurkat cells were transfected with plasmids encoding for either Smac siRNA or nonsense sequence 
or vector without insert as described in “Material and Methods”. Cells were left untreated (CO) or 
treated with cephalostatin 2 (CPH; 50 nM) for the indicated times. Apoptotic cells were quantified 
by flow cytometry as described in “Materials and Methods”. Downregulation was verified by 
Western blot. Equal protein loading was controlled by staining membranes with Ponceau S (a 
representative section of the stained membrane is shown). All experiments were carried out three 
times. Bars, the mean ± SE of three independent experiments performed in triplicate. (*, P < 0.05; 
**, P < 0.01 unpaired two-tailed t test) 
 
Caspase-9 is known to be an important initiator caspase in cephalostatin mediated 
cell death (17). As shown in Figure III.25 cephalostatin activates caspase-9. The 
importance of caspase-9 was investigated in caspase-9 deficient and caspase-9 
reconstituted Jurkat cells. Apoptosis was almost completely prevented in caspase-
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9 deficient cells. Since Smac is known to abolish the inhibitory effect of XIAP on 
caspase-9 and -3, we investigated the effect of Smac downregulation on 
cephalostatin-mediated caspase activation.  
 
0
20
40
60
9+/+
9-/-
%
 a
po
pt
ot
ic
ce
lls
CO 50nM CPH
***
Procasp-9
9+/+      9-/-
Ponceau S
CO
CPH (h)
241684
Procasp-9 (47 kDa)
p37/35
Ponceau S
 
Figure III.25 Caspase-9 is essential for cephalostatin-induced cell death 
Upper panel: Jurkat cells were left untreated (CO) or treated with cephalostatin 2 (CPH; 50 nM) for 
the indicated times. Activation of caspase-9 was examined by Western blot. Equal protein loading 
was controlled by staining membranes with Ponceau S (a representative section of the stained 
membrane is shown). All experiments were carried out three times. Lower panel: Caspase-9 
deficient (9-/-) and caspase-9 reconstituted Jurkat (9+/+) cells were left untreated (CO) or treated 
with 50 nM cephalostatin 2 (CPH) for 24 hours. Apoptotic cells were quantified by flow cytometry as 
described in “Materials and Methods”. Bars, the mean ± SE of three independent experiments 
performed in triplicate. (***, P < 0.001 unpaired two-tailed t test). Protein extracts from 9-/- and 9+/+ 
cells were prepared and caspase-9 level analyzed by Western Blot. Equal protein loading was 
controlled by staining membranes with Ponceau S (a representative section of the stained 
membrane is shown). 
 
7.3 SMAC ENHANCES THE APOPTOTIC SIGNALING CASCADE 
 
Silencing of Smac clearly suppressed the appearance of caspase-9 cleavage 
products indicating a reduced activation of the initiator caspase-9 in Smac-
depleted cells, whereas the activation of the initiator caspase-4 remained 
unaffected (Figure III.26 A). Smac siRNA had also influence on caspase-3 
activation and consequently PARP cleavage as shown in Figure III.26 B by 
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reduced caspase-3 cleavage products and strongly diminished appearance of the 
85 kDa PARP cleavage product. Caspase-2 has characteristics of initiator 
caspase due to its long CARD-containing prodomain. The prodomain and the 
linker region between the large and the small subunit are removed during 
generation of the active enzyme resulting in different cleavage products (27, 87).  
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Figure III.26 Smac silencing reduces activation of caspase-9, caspase-3 and caspase-2 but 
not caspase-4. 
Jurkat cells were transfected with plasmids encoding for either Smac siRNA, nonsense sequence 
or with vector alone as described in “Materials and Methods”. Cells were left untreated (CO) or 
treated with cephalostatin 2 (CPH; 50 nM) for the indicated times. Activation of caspase-9, 
caspase-2, caspase-3 and caspase-4 as well as PARP cleavage was examined by Western blot. 
Equal protein loading was controlled by staining membranes with Ponceau S (a representative 
section of the stained membrane is shown). All experiments were carried out three times. 
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Interestingly, cephalostatin-induced processing of caspase-2 to its 18 kDa 
fragment was prevented upon Smac silencing (Figure III.26 A), pointing to a 
participation of caspase-2 in cephalostatin-induced cell death. 
 
 
8 INVOLVEMENT OF CASPASE-2 IN CEPHALOSTATIN-
INDUCED APOPTOSIS 
8.1 CASPASE-2 PARTICIPATES IN APOPTOSIS INDUCTION 
 
In fact, treatment of cells with cephalostatin leads to an early activation of 
caspase-2 as demonstrated in Figure III.27 A by the appearance of the caspase-2 
cleavage product p31 already after 8 h of incubation.  
For investigating the impact of caspase-2 in cephalostatin-induced apoptosis, 
caspase-2 was inhibited by use of the selective inhibitor zVDVADfmk and by 
siRNA. Use of zVDVADfmk (Figure III.27 B left panel; experiment performed by 
Dr. Nancy López-Antón) significantly inhibits cephalostatin-mediated apoptosis.  
Cells transiently transfected with a siRNA targeting caspase-2 showed a 
significantly reduced amount of annexin V positive cells compared to cells 
transfected with a nonsense siRNA sequence (Figure III.27 B right panel). These 
results indicate that caspase-2 contributes to cephalostatin-mediated apoptosis. 
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Figure III.27 Cephalostatin activates caspase-2 
A) Jurkat cells were either left untreated (CO) or treated with 50 nM cephalostatin (CPH) for the 
indicated times. Caspase-2 activation was examined by Western blot. B) Left panel: Jurkat cells 
were left untreated (CO) or treated with cephalostatin 2 (CPH; 50 nM). Cells were preincubated 
with 25 µM PANcaspase inhibitor zVADfmk for 1 h. Apoptotic cells were analyzed by flow 
cytometry as described in “Materials and Methods”. Right panel: Cells were transfected with either 
caspase-2 siRNA or scramble siRNA and left untreated (CO) or treated with cephalostatin 2 (CPH; 
50 nM). Apoptotic cells were analyzed by Annexin staining as described in “Materials and 
Methods”. Downregulation of caspase-2 was verified by Western blot analysis. Equal protein 
loading was controlled by staining membranes with Ponceau S (a representative section of the 
stained membrane is shown). All experiments were carried out three times. Bars, the mean ± SE of 
three independent experiments performed in triplicate. (*, P < 0.05; **, P < 0.01 unpaired two-tailed 
t test). 
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8.2 CASPASE-2 IS ACTIVATED INDEPENDENT OF CASPASE-9 
UPON CEPHALOSTATIN TREATMENT. 
 
Caspase-2 can be activated upstream (88, 89) or downstream (90) of caspase-9. 
We hypothesized that, in addition to caspase-4, caspase-2 could act as an apical 
caspase in cephalostatin-induced apoptosis.  
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Figure III.28 Caspase-2 is activated independent of caspase-9 
Upper panel: Jurkat cells lacking caspase-9 (Caspase-9-/-) were either left untreated (CO) or 
treated with cephalostatin 2 (CPH; 50 nM) or thapsigargin (TG; 3 µM) for the indicated times. 
Processing of procaspase-2 was examined by Western blot. Lower panel: Jurkat cells were 
transfected with caspase-2 siRNA or scramble siRNA and left either untreated (CO) or treated with 
cephalostatin 2 (CPH, 50 nM) for the indicated times. Caspase-9 processing was examined by 
Western blot. Equal protein loading was controlled by staining membranes with Ponceau S (a 
representative section of the stained membrane is shown).  
 
To this end, activation of caspase-2 was examined in caspase-9-deficient cells 
and activation of caspase-9 was investigated in caspase-2-silenced cells. 
Caspase-2 activation upon cephalostatin treatment as well as by thapsigargin is 
independent of an activated caspase-9, as shown using caspase-9-deficient Jurkat 
cells (Caspase 9-/-,Figure III.28 upper panel). On the other hand, caspase-9 is 
activated to the same extent in caspase-2 silenced cells as in cells transfected 
with scramble siRNA (Figure III.28 lower panel). Thus, cephalostatin-induced 
III RESULTS 
 
74 
caspase-2 does not affect caspase-9 activation which differs from the role of 
cephalostatin-induced caspase-4.  
Caspase-2 acts as initiator caspase and independently from caspase-9. In a next 
step we were interested in the mechanism of this initial caspase-2 activation 
induced by cephalostatin.  
 
 
9 CEPHALOSTATIN INDUCES THE FORMATION OF 
THE PIDDOSOME COMPLEX. 
 
Although processing of caspase-2 to its active fragments was observed after 8 
hours of treatment with cephalostatin, similarly to caspase-9, recruitment to a large 
protein complex (independent of the Apaf-1 apoptosome) is sufficient to mediate 
its activation (91).  
Later on, appearance of cleavage fragments is mediated by self-processing and 
further enhances its catalytic activity (27, 87). This newly identified caspase-2 
activating protein complex is referred to as the PIDDosome (56), composed of the 
proteins PIDD, RAIDD and procaspase-2. To investigate the participation of the 
PIDDosome in our system we studied the protein interaction by 
immunoprecipitation of caspase-2, RAIDD and PIDD. Western blot analysis of the 
precipitation complex of each antibody reveals the basal interaction of RAIDD and 
PIDD in untreated cells (Figure III.29). 
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Figure III.29 The PIDDosome is formed upon cephalostatin treatment 
Jurkat cells were either left untreated (CO) or treated with cephalostatin 2 (CPH; 50 nM), 
thapsigargin (TG; 3 µM) or etoposide (Eto, 2 µM) for 1h. Caspase-2, PIDD or RAIDD were 
immunoprecipitated as described in “Materials and Methods” and caspase-2, PIDD and RAIDD 
levels were detected by Western blot. 
 
Importantly, upon 1 h of incubation with cephalostatin procaspase-2 is recruited to 
the PIDD and RAIDD complex (Figure III.29), suggesting the assembly of the 
PIDDosome as the possible mechanism of caspase-2 activation.  
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IV DISCUSSION 
 
Many chemotherapeutic drugs used in cancer therapy induce apoptosis via the 
extrinsic or the intrinsic pathway. Since accumulation of chemoresistance is often 
connected to defects in these apoptotic signaling pathways, it is of high interest to 
find novel mechanisms for tumor cell death induction. The cephalostatins are 
promising substances in this context, particularly because cephalostatin mediates 
cell death apoptosome- and CD95/caspase-8-independent (15). Therefore, 
cephalostatin-induced cell death mechanisms were further investigated to find 
potentially new targets for cancer therapy. 
 
 
1 COMPARISON OF CEPHALOSTATIN 2, 10 AND 12 
 
Structure-activity studies have been performed on different cephalostatins. The 
results indicate that the Northern part is the most shared unit among the 
cephalostatins and is also strongly associated with antitumor activity (18). This is 
in line with cephalostatin 10 showing dose dependencies comparable to 
cephalostatin 1 and 2 (6, 7, 10), whereas an increased level of hydroxylation in the 
Southern part results in a decrease in antitumor activity, as in the case of 
cephalostatin 12 (18). In the present work, cytotoxicity of CPH 2, 10 and 12 was 
tested on Jurkat leukemia T cells and the results obtained from MTT-test (IC50 for 
CPH 2: 1 nM, CPH 10: 9.7 nM and CPH 12: 560 nM) and from measurement of 
DNA-fragmentation showed that CPH 2 is more potent than CPH 10 and CPH 12. 
This corresponds to the expected pattern that their potency varies depending on 
the chemical composition (Figure I.2).  
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2 CELL TYPE INDEPENDENT APOPTOSIS INDUCTION 
 
To investigate whether cephalostatin is able to induce apoptosis independent of 
cell type, various cell lines were tested: the cervix carcinoma cell line HeLa, the 
breast adenocarcinoma cell line MCF-7, the malignant melanoma cell line SK-Mel-
5 and the ovarian cancer cell line SK-OV-3. In the entire listed cell lines 
cephalostatin is able to induce apoptosis, manifesting cell type independence, 
even though except for HeLa a higher cephalostatin concentration is needed for 
cell death induction in MCF-7, SK-OV-3 and SK-Mel-5 cells. Since SK-OV-3 has 
dysfunctional apoptosome activity (92) and SK-Mel-5 cells are shown to have very 
low Apaf 1 levels (93, 94), there is further evidence that apoptosome formation is 
not necessary for cephalostatin induced cell death. Melanoma is a very aggressive 
form of cancer being highly resistant to most therapies (95) due to inactivation of 
the apoptotic machinery (96). For that reason a long term assay was employed. 
Cephalostatin induced almost complete inhibition of clonal tumor growth contrary 
to taxol, although taxol is able to induce DNA-fragmentation in the short-time 
Nicoletti assay. This result highlights the potential of cephalostatin to fight on 
chemoresistance, since a very short treatment time (2 h) is sufficient to induce 
complete tumor cell growth inhibition. 
 
 
3 INVOLVEMENT OF CASPASES 
 
Caspases are the main executioners of classical apoptotic cell death. 
Cephalostatin mediated apoptosis is almost completely caspase-dependent in 
Jurkat (15) and HeLa cells, but the apoptosis in MCF-7 cells lacking caspase-3 is 
not diminished compared to caspase-3 reconstituted cells. Since this cell line still 
expresses other effector caspases, caspase-7 (97) maybe compensating for 
caspase-3. Surprisingly, cephalostatin induces caspase-independent cell death in 
the more resistant SK-OV-3 and SK-Mel-5 cell lines, as shown by the use of the 
broad spectrum caspase inhibitor zVADfmk. To control these results another 
caspase inhibitor, Q-VD-OPh (98), was tested in SK-Mel-5. Again, DNA-
fragmentation could not be blocked. One could presume, that these inhibitors can 
not operate because of inactivation or increased efflux, but several studies show 
an inhibitory influence of zIETDfmk (caspase-8 inhibitor) (99) or zVADfmk (100), 
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on DNA-fragmentation or PARP cleavage (101) in SK-Mel-5 cells, clearly 
demonstrating its activity. Upon this interesting finding cell death induction in SK-
Mel-5 cells was further investigated. 
 
 
4 CELL DEATH INDUCTION IN SK-MEL-5 CELLS 
 
The normally transiently activated and strictly controlled transcription factor STAT3 
is constitutively activated at 50 – 90% frequency in human cancers, including 
melanoma and is amongst other factors critically involved in tumor cell growth by 
regulating the expression of genes that contribute to survival and proliferation. 
Interestingly, a permanent STAT3 activation was observed in a majority of tested 
melanoma cell lines and primary melanoma but not in normal skin from the same 
patients, making STAT3 a highly interesting therapeutic target (61, 102).  
Studies have shown that overexpression of STAT3 results in elevated levels of the 
antiapoptotic proteins survivin, Bcl-xL and Mcl-1 and of the cell cycle regulators 
cyclin D1 and c-Myc, which regulate the G1 to S transition. Inhibition of STAT3 by 
dominant negative mutants leads to the downregulation of the above named 
STAT3 targets and to cell cycle arrest in G1 phase (37, 103).  
First experiments show that cephalostatin induces not only the degradation of the 
Ser 727 and Tyr 705 phosphorylated STAT3 proteins but also degradation of the 
total STAT3 protein. This is in contrast to other studies with apoptosis inducing 
compounds (103), where total protein levels are not affected. Therefore, it has to 
be further explored whether STAT3 protein (e.g. by proteasome or lysosome) or 
mRNA level is affected.  
Cell cycle analysis revealed that upon cephalostatin treatment cells are 
significantly arrested in G1 phase. If this arrest is a consequence of STAT3 
inhibition has to be further investigated by studying the STAT3 regulated cell cycle 
related proteins cyclin D1 and c-Myc. As a second downstream target of STAT3 
survivin protein was examined and was observed to be completely degraded by 
cephalostatin. Following survivin downregulation the release of proapoptotic 
factors from mitochondria such as cytochrome c and AIF is described (62). Since 
cephalostatin induces caspase-independent DNA-fragmentation in SK-Mel-5 the 
impact of AIF was investigated, but contrary to other studies (101, 104) AIF is not 
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involved in cephalostatin-mediated DNA-fragmentation, suggesting that other 
caspase-independent factors like EndoG or Omi/HtrA2 could be responsible for 
DNA-fragmentation. 
The late DNA-fragmentation, independence of caspases and the remarkable 
protein degradation of STAT3 and survivin in SK-Mel-5 leads to the suggestion 
that an alternative apoptosis pathway like autophagy could be induced. Autophagy 
(25, 105) is a non-apoptotic form of programmed cell death characterized by 
caspase-independence, very late (if at all) DNA-fragmentation and increased 
lysosomal activity, leading to degradation of cytosolic content in large autophagic 
vesicles. If cephalostatin induces autophagy and the related formation of 
autophagosomes is under current investigation by transmission electron 
microscopy.  
 
 
5 MECHANISM OF SMAC RELEASE 
 
The release of mitochondrial intermembrane space proteins to the cytosol is a key 
event during apoptosis. For instance cytochrome c is required for the initiation of 
the apoptosome and activation of caspases whereas Smac/DIABLO is believed to 
enhance caspase activation through the neutralization of the inhibitor of apoptosis 
proteins (106). Upon apoptotic stimuli these mitochondrial factors are usually 
released together in a manner that is coordinately initiated (107). Thus, the fact 
that cephalostatin leads to a marked and early Smac release without detectable 
amounts of cytochrome c deserves attention and asks for the mechanism of 
release as well as for the impact of Smac in cephalostatin-induced cell death. 
Similar to our data, the group of Anderson (78, 108) reported about an Apaf-
1/cytochrome c-independent and Smac-dependent induction of apoptosis in 
multiple myeloma cells by dexamethasone. The authors identified activated JNK to 
be responsible for Smac release using the JNK inhibitor SP600125. Cephalostatin 
is also able to rapidly induce JNK activation (16). However, blocking JNK activity 
via SP600125 or overexpression of a dominant-negative form of its upstream 
kinase ASK1 in our hands did not affect Smac release. Furthermore, inhibition of 
caspase-2, which has been reported to directly induce release of mitochondrial 
proteins, did neither influence Smac release. First experiments show that 
overexpression of the antiapoptotic Bcl-2 family member Bcl-xL (15) as well as the 
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absence of the proapoptotic Bcl-2 protein Bak delays, but can not inhibit Smac 
release, suggesting that cephalostatin may trigger a signal directly influencing the 
mitochondrial pore formation. Furthermore, cell death by cephalostatin was not 
inhibited by Bak deficiency. Contrary, staurosporine- and etoposide-induced 
apoptosis was inhibited, further pointing to a cytochrome c independent and Smac 
dependent mechanism for cephalostatin.  
The calpain family of proteases seems to be an important factor in the induction of 
apoptosis via mitochondria, since Bax has been identified as a target of calpain 
(109) and calpain inhibition has been shown to inhibit the release of Smac and 
cytochrome c from mitochondria (86). Calpain is rapidly activated upon 
cephalostatin treatment and is partially involved in the selective Smac release, 
further supporting the crosstalk between calpain and mitochondria. Further studies 
will focus on details regarding the selective release of Smac and its underlying 
mechanism.  
 
 
6 IMPACT OF SMAC ON APOPTOSIS 
 
Smac has been discovered in the search for proteins which are able to interact 
with mammalian and baculoviral IAPs (110). IAPs, which are characterized by one 
or more baculovirus IAP repeat (BIR) domains antagonize caspases by binding to 
and inhibiting mainly caspase-9, -3 and -7 (111). Smac has been reported to 
promote apoptosis in response to various apoptosis inducers by antagonizing IAP-
mediated inhibition of caspases (35). If Smac is important in cephalostatin induced 
cell death it thus should counteract XIAP overexpression. This could clearly be 
shown in XIAP overexpressing Jurkat cells in comparison to wildtype Jurkat cells, 
whereas etoposide mediated cell death is almost completely inhibited. To this end 
Smac agonists sensitized various tumor cells for cell death (112, 113). We used 
siRNA technique to silence the Smac gene and subsequently examined the impact 
of endogenous Smac released upon cephalostatin treatment. As expected, we 
observed a strong reduction in caspase-9 as well as caspase-3 activation. No 
effect of caspase-4 activation in Smac-depleted cells was seen. Taken together, 
our results demonstrate an essential role of Smac in cephalostatin-induced 
caspase cascade most likely by promoting caspase activity. In this respect, the 
fact that caspase-2 activity triggered by cephalostatin is markedly reduced in cells 
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depleted by Smac draws attention to caspase-2 as a further caspase involved in 
the apoptosome-independent cell death induced by cephalostatin.  
 
 
7 INVOLVEMENT OF CASPASE-2 
 
Even though caspase-2 was the second mammalian caspase identified, its exact 
role in the regulation of cell death is controversial and relatively unknown, in part 
due to its different function dependent on cell type and stimulus. Caspase-2 
contains a CARD domain and can act as initiator caspase (72, 88, 89) but has 
characteristics of effector caspases (114, 115). It is localized predominantly to the 
Golgi complex and the nucleus, but also in mitochondria and cytosol (116).  
Many reports, including studies employing caspase-2-deficient mice, exclude an 
essential role of caspase-2 in apoptosis presumably due to the compensation by 
other caspases (90, 117, 118). However, caspase-2 is activated in response to 
DNA damage, where it acts as the only initiator caspase (116), and appears 
necessary for apoptosis triggered by UV (ultraviolet) irradiation (72), trophic factor 
withdrawal (119), serum deprivation (120) or administration of TRAIL (121, 122). 
Caspase-2 has been also implicated in neuronal death induced by β-amyloid (123) 
and recently in ER stress (124, 125, 126).  
We depleted caspase-2 via siRNA transfection and observed a minor but 
significant effect on the extent of apoptotic cell death induced by cephalostatin. 
Use of the rather selective inhibitor of caspase-2 zVDVAD-fmk results in a similar 
reduction of cell death indicating that caspase-2 is involved in the unusual 
apoptotic pathway induced by cephalostatin. The question arises as to whether 
caspase-2 is functioning as an initiator or as an effector caspase. Both roles have 
been described (72, 89, 90). The fact that caspase-2 is activated in caspase-9-
deficient cells similarly to parental Jurkat cells clearly votes for caspase-2 
activation to be an upstream event.  
Caspase-2 has been reported to engage directly the mitochondrial apoptotic 
pathway by inducing release of mitochondrial factors (81, 82, 83, 122, 127). We 
show that caspase-2 induced by cephalostatin is not involved in Smac release. 
Importantly, caspase-2 activation is not involved in apoptosome-independent 
activation of caspase-9 as reported previously for cephalostatin-induced caspase-
4.  
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Our next step was to understand how caspase-2 is activated upon cephalostatin 
treatment. In this respect, most interestingly caspase-2 was reported to be 
activated by recruitment into a large multiprotein complex independently of Apaf-1 
and cytochrome c (91). This putative complex has been proposed to be the 
PIDDosome (56), formed by association of the protein PIDD (p53-induced protein 
with a DD), RAIDD (RIP associated ICH-1/CED-3-homologous protein with DD) 
and procaspase-2. The PIDDosome was proposed to regulate caspase-2 
activation and apoptosis induced by genotoxic agents. Upon recruitment to the 
complex, caspase-2 was activated and autoprocessed, but it was not clear 
whether activated caspase-2 was involved in cell death (56). RAIDD together with 
caspase-2 has been recently demonstrated to participate in the induction of 
apoptosis under conditions of trophic factor withdrawal but not DNA damage (119), 
arguing against the exclusive formation of the caspase-2 activation complexes by 
genotoxic stress (56). Along this line cephalostatin does not induce DNA damage 
(16) and is to our best knowledge one of the few drugs (128, 129) which has 
clearly shown to induce recruitment of caspase-2 to PIDD and RAIDD leading to 
formation of the PIDDosome.  
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V SUMMARY 
 
The presented work reports unusual apoptotic signaling pathways induced by the 
experimental chemotherapeutic drug cephalostatin with the following new findings: 
 
Cephalostatin induces apoptosis independent of cell type. 
Apoptosis induction was investigated in leukemia (Jurkat), breast adeno-
carcinoma (MCF-7), cervix carcinoma (HeLa), ovarian cancer (SK-OV-3) and 
melanoma (SK-Mel-5) cell lines. In all cell lines cell death could be induced, 
proving the usability of cephalostatin for cancer treatment. Interestingly, 
cephalostatin induces caspase-dependent cell death in Jurkat and HeLa cells, but 
caspase-independent apoptosis in SK-OV-3 and SK-Mel-5 cells. Thus, the 
mechanism of apoptosis induction seems to be cell dependent.  
 
Cephalostatin-induced cell death in SK-Mel-5 cells. 
Due to the surprising fact that caspases are not involved in apoptosis induction in 
SK-Mel-5 cells, the cell death induction by cephalostatin was further investigated 
in this cell line. AIF, a classical caspase-independent apoptosis mediator, is not 
involved in DNA-fragmentation. Interestingly, cephalostatin induces cell cycle 
arrest in G1 phase and the transcription factor STAT3 and the IAP survivin were 
identified as targets. 
 
Mechanism of selective Smac – release from mitochondria. 
Smac – not cytochrome c – is predominately released from mitochondria of 
cephalostatin treated cells. Neither JNK nor caspase-2 is responsible for the 
selective release. First experiments show that calpain, which is rapidly activated 
upon cephalostatin treatment, is partially involved in Smac release.  
 
Smac enhances the apoptotic signaling cascade in Jurkat leukemia T cells. 
Smac was demonstrated to have significant impact on cephalostatin-induced 
apoptosis. This was due to increased caspase activity. Caspase-4 which is known 
to be activated by cephalostatin (17) was not influenced. Interestingly, apart from 
caspase-9, caspase-3 and PARP mainly caspase-2 activity was affected by Smac. 
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Caspase-2 is involved in apoptosis induction in Jurkat T cells. 
Cephalostatin has been reported previously to activate caspase-9 apoptosome-
independent and partially via ER stress (17). Caspase-2 acts as a further initiator 
caspase and contributes independent of caspase-9 to cephalostatin-induced cell 
death. 
 
Cephalostatin induces the formation of the PIDDosome. 
The PIDDosome is large protein complex, implicated in the activation of caspase-
2. Cephalostatin is one of the few drugs, known so far, able to induce the 
formation of this complex consisting of caspase-2, RAIDD and PIDD. 
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Figure V.1 Summary of cephalostatin-induced cell death mechanisms 
 
In summary, the experimental drug cephalostatin 2, which was isolated from a 
marine organism, proved to be both a very valuable tool to discover novel aspects 
in apoptotic signaling such as recruitment of a PIDDosome responsible for 
caspase-2 activation as well a promising therapeutic agent promoting caspase-
independent apoptosis in chemoresistant melanoma cells. 
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